UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_____________________________________

FORM 10-Q

_____________________________________



ý☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2017~~2023



¨☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER 000-52008

~~_____________________________________~~

LUNA INNOVATIONS INCORPORATED

(Exact name of registrant as specified in its charter)

_____________________________________



Delaware						54-1560050
(State or Other Jurisdiction of Incorporation or Organization)						(I.R.S. Employer Identification Number)

301 First Street SW, Suite 200

Roanoke, VA 24011

(Address of Principal Executive Offices)

(540) 769-8400

(Registrant’s Telephone Number, Including Area Code)

_____________________________________

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value per share	LUNA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ý☒ Yes ¨☐ No

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). ý☒ Yes ¨☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o☐Accelerated filer o☐

Non-accelerated filer o ~~(Do not check if a smaller reporting company)~~ ☒Smaller reporting company ý☒

Emerging growth company o☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨☐ Yes ý☒ No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of November ~~9, 2017,~~10, 2023, there were ~~28,402,887~~33,958,641 shares of the registrant’s common stock outstanding.

Table of Contents

LUNA INNOVATIONS INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, ~~2017~~2023

TABLE OF CONTENTS

Table of Contents

PART I. FINANCIAL INFORMATION



ITEM 1.			FINANCIAL STATEMENTS

Luna Innovations Incorporated

Consolidated Balance Sheets

(Unaudited)

September 30, 2017 December 31, 2016
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 38,514,437
$ 12,802,458
Accounts receivable, net 8,940,405
10,269,012
Inventory 7,300,035
6,848,835
Prepaid expenses and other current assets 924,196
1,375,659
Current assets held for sale —
5,801,629
Total current assets 55,679,073
37,097,593
Property and equipment, net 3,145,769
3,482,687
Intangible assets, net 3,264,285
3,367,217
Goodwill 502,000
502,000
Long term receivable- sale of HSOR business 4,000,000
—
Other assets 18,024
38,194
Non-current assets held for sale —
10,509,282
Total assets $ 66,609,151
$ 54,996,973
Liabilities and stockholders’ equity
Liabilities:
Current liabilities:
Current portion of long-term debt obligations $ 1,833,333
$ 1,833,333
Current portion of capital lease obligations 49,070
52,128
Accounts payable 2,188,776
2,954,742
Accrued liabilities 9,586,554
7,913,544
Deferred revenue 897,023
837,906
Current liabilities held for sale —
2,376,703
Total current liabilities 14,554,756
15,968,356
Long-term deferred rent 1,221,170
1,319,402
Long-term debt obligations 1,057,263
2,420,032
Long-term capital lease obligations 79,246
114,940
Non-current liabilities held for sale —
84,555
Total liabilities 16,912,435
19,907,285
Commitments and contingencies

Stockholders’ equity:
Preferred stock, par value $0.001, 1,321,514 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016 1,322
1,322
Common stock, par value $0.001, 100,000,000 shares authorized, 28,402,887 and 27,988,104 shares issued, 27,815,060 and 27,541,277 shares outstanding at September 30, 2017 and December 31, 2016 29,074
28,600
Treasury stock at cost, 587,827 and 446,827 shares at September 30, 2017 and December 31, 2016 (746,007 ) (517,987 )
Additional paid-in capital 83,204,263
82,451,958
Accumulated deficit (32,791,936 ) (46,874,205 )
Total stockholders’ equity 49,696,716
35,089,688
Total liabilities and stockholders’ equity $ 66,609,151
$ 54,996,973
(in thousands, except share data)


	September 30, 2023		December 31, 2022

Assets
Current assets:
Cash and cash equivalents	$	6,028	$	6,024
Accounts receivable, net	39,304		33,249
Contract assets	7,324		7,691
Inventory	43,318		36,582
Prepaid expenses and other current assets	4,207		4,328

Total current assets	100,181		87,874
Property and equipment, net	4,892		4,893
Intangible assets, net	16,143		18,750
Goodwill	26,896		26,927

Operating lease right-of-use assets	7,999		4,661
Other non-current assets	3,338		3,255
Deferred tax asset	5,645		4,647

Total assets	$	165,094	$	151,007
Liabilities and stockholders’ equity
Liabilities:
Current liabilities:
Current portion of long-term debt obligations	$	3,000	$	2,500

Accounts payable	10,617		8,109
Accrued and other current liabilities	14,705		16,694
Contract liabilities	4,619		4,089
Current portion of operating lease liabilities	2,069		2,239


Total current liabilities	35,010		33,631
Long-term debt obligations, net of current portion	28,887		20,726
Long-term portion of operating lease liabilities	6,178		2,804


Other long-term liabilities	407		444


Total liabilities	70,482		57,605
Commitments and contingencies (Note 11)
Stockholders’ equity:

Common stock, par value $0.001, 100,000,000 shares authorized, 35,781,127 and 34,901,954 shares issued, 33,943,453 and 33,105,080 shares outstanding at September 30, 2023 and December 31, 2022, respectively	36		35
Treasury stock at cost, 1,837,674 and 1,796,862 shares at September 30, 2023 and December 31, 2022, respectively	(6,043)		(5,607)
Additional paid-in capital	109,634		104,893
Accumulated deficit	(5,273)		(2,296)
Accumulated other comprehensive loss	(3,742)		(3,623)
Total stockholders’ equity	94,612		93,402
Total liabilities and stockholders’ equity	$	165,094	$	151,007

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Luna Innovations Incorporated

Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022


Revenue	$	30,703	$	29,153	$	84,912	$	77,795
Cost of revenue	13,074		12,234		35,445		30,633
Gross profit	17,629		16,919		49,467		47,162
Operating expense:
Selling, general and administrative	12,829		11,678		39,565		39,733
Research, development and engineering	2,719		2,776		8,257		7,983
Amortization of intangible assets	929		987		2,839		2,794
Total operating expense	16,477		15,441		50,661		50,510
Operating income/(loss)	1,152		1,478		(1,194)		(3,348)
Other income/(expense):

Other income	115		73		98		146
Interest expense, net	(613)		(218)		(1,566)		(442)
Total other expense, net	(498)		(145)		(1,468)		(296)
Income/(loss) from continuing operations before income taxes	654		1,333		(2,662)		(3,644)
Income tax expense/(benefit)	193		165		(723)		(527)

Net income/(loss) from continuing operations	461		1,168		(1,939)		(3,117)
Income/(loss) from discontinued operations, net of income tax expense/(benefit) of $—, $(78), $(346), and $3,205.	—		28		(1,038)		622
Gain on sale of discontinued operations, net of tax of $3,117	—		—		—		10,921
Net income/(loss) from discontinued operations	—		28		(1,038)		11,543
Net income/(loss)	461		1,196		(2,977)		8,426


Net income/(loss) per share from continuing operations:
Basic	$	0.01	$	0.04	$	(0.06)	$	(0.10)
Diluted	$	0.01	$	0.03	$	(0.06)	$	(0.10)
Net income/(loss) per share from discontinued operations:
Basic	$	—	$	0.00	$	(0.03)	$	0.36
Diluted	$	—	$	0.00	$	(0.03)	$	0.36
Net income/(loss) per share attributable to common stockholders:
Basic	$	0.01	$	0.04	$	(0.09)	$	0.26
Diluted	$	0.01	$	0.04	$	(0.09)	$	0.26
Weighted average shares:
Basic	33,917,700		32,800,690		33,631,654		32,492,276
Diluted	35,218,547		34,104,850		33,631,654		32,492,276

Three Months Ended
September 30, Nine Months Ended
September 30,
2017 2016 2017 2016
(unaudited) (unaudited)
Revenues:
Technology development $ 4,590,054
$ 4,118,245
$ 13,428,428
$ 11,772,731
Products and licensing 7,052,094
7,066,908
19,593,648
18,301,631
       Total revenues 11,642,148
11,185,153
33,022,076
30,074,362
Cost of revenues:
Technology development 3,491,840
3,068,360
10,045,261
8,986,312
Products and licensing 3,617,547
3,758,765
10,201,459
9,954,987
       Total cost of revenues 7,109,387
6,827,125
20,246,720
18,941,299
Gross profit 4,532,761
4,358,028
12,775,356
11,133,063
Operating expense:
Selling, general and administrative 3,256,074
3,816,679
10,345,964
11,296,389
Research, development and engineering 833,811
812,050
2,581,473
2,789,801
       Total operating expense 4,089,885
4,628,729
12,927,437
14,086,190
Operating income/(loss) 442,876
(270,701 ) (152,081 ) (2,953,127 )
Other income/(expense):
Other expense (3,389 ) (231 ) (4,258 ) (1,904 )
Interest expense (55,099 ) (71,991 ) (179,860 ) (237,081 )
Total other expense (58,488 ) (72,222 ) (184,118 ) (238,985 )
Income/(loss) from continuing operations before income taxes 384,388
(342,923 ) (336,199 ) (3,192,112 )
Income tax (benefit)/expense (130,977 ) 44,797
(63,350 ) (173,801 )
Net income/(loss) from continuing operations 515,365
(387,720 ) (272,849 ) (3,018,311 )
Income/(loss) from discontinued operations, net of income tax (benefit)/expense of $(349,515), $(35,095), $(349,515), and $209,678. 145,293
(57,358 ) (644,241 ) 342,685
Gain on sale, net of $1,508,373 of related income taxes 15,096,666
—
15,096,666
—
Net income/(loss) from discontinued operations 15,241,959
(57,358 ) 14,452,425
342,685
Net income/(loss) 15,757,324
(445,078 ) 14,179,576
(2,675,626 )
Preferred stock dividend 33,699
28,941
97,331
74,731
Net income/(loss) attributable to common stockholders $ 15,723,625
$ (474,019 ) $ 14,082,245
$ (2,750,357 )
Net income/(loss) per share from continuing operations:
       Basic $ 0.02
$ (0.01 ) $ (0.01 ) $ (0.11 )
       Diluted $ 0.02
$ (0.01 ) $ (0.01 ) $ (0.11 )
Net income/(loss) per share from discontinued operations:
       Basic $ 0.55
$ 0.00
$ 0.52
$ 0.01
       Diluted $ 0.47
$ 0.00
$ 0.52
$ 0.01
Net income/(loss) per share attributable to common stockholders:
        Basic $ 0.57
$ (0.02 ) $ 0.51
$ (0.10 )
        Diluted $ 0.48
$ (0.02 ) $ 0.51
$ (0.10 )
Weighted average common shares and common equivalent shares outstanding:
        Basic 27,692,539
27,605,028
27,611,905
27,531,730
        Diluted 32,714,389
27,605,028
27,611,905
27,531,730

Table of Contents

Luna Innovations Incorporated

Consolidated Statements of Comprehensive (Loss)/Income (Unaudited)

(in thousands)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net income/(loss)	$	461	$	1,196	$	(2,977)	$	8,426
Other comprehensive loss	(1,564)		(3,124)		(119)		(6,721)
Total other comprehensive (loss)/income	$	(1,103)	$	(1,928)	$	(3,096)	$	1,705

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Luna Innovations Incorporated

Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

(in thousands, except share data)


		Three Months Ended September 30, 2023
	Common Stock		Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total
		Shares	$		Shares	$		$		$		$		$
Balance, June 30, 2023		33,908,336	$	36	1,831,491	$	(5,960)	$	108,709	$	(5,734)	$	(2,178)	$	94,873
Exercise of stock options		11,782	—		—	—		37		—		—		37
Share-based compensation		23,335	—		—	—		888		—		—		888



Purchase of treasury stock		—	—		6,183	(83)		—		—		—		(83)



Net income		—	—		—	—		—		461		—		461
Foreign currency translation adjustment		—	—		—	—		—		—		(1,564)		(1,564)
Balance, September 30, 2023		33,943,453	$	36	1,837,674	$	(6,043)	$	109,634	$	(5,273)	$	(3,742)	$	94,612


		Three Months Ended September 30, 2022
	Common Stock		Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total
		Shares	$		Shares	$		$		$		$		$
Balance, June 30, 2022		32,752,348	35		1,784,957	(5,542)		102,043		(4,345)		(3,630)		$	88,561
Exercise of stock options		82,018	—		—	—		3		—		—		3
Share-based compensation		31,504	—		—	—		1,218		—		—		1,218







Net income		—	—		—	—		—		1,196		—		1,196
Foreign currency translation adjustment		—	—		—	—		—		—		(3,124)		(3,124)
Balance, September 30, 2022		32,865,870	$	35	1,784,957	$	(5,542)	$	103,264	$	(3,149)	$	(6,754)	$	87,854

Table of Contents


		Nine Months Ended September 30, 2023
	Common Stock		Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total
		Shares	$		Shares	$		$		$		$		$
Balance, December 31, 2022		33,105,080	$	35	1,796,862	$	(5,607)	$	104,893	$	(2,296)	$	(3,623)	$	93,402
Exercise of stock options		529,802	—		—	—		1,271		—		—		1,271
Share-based compensation		254,883	1		—	—		2,924		—		—		2,925

ESPP issuance		88,317	—		—	—		546		—		—		546

Purchase of treasury stock		(34,629)	—		40,812	(436)		—		—		—		(436)



Net loss		—	—		—	—		—		(2,977)		—		(2,977)
Foreign currency translation adjustment		—	—		—	—		—		—		(119)		(119)
Balance, September 30, 2023		33,943,453	$	36	1,837,674	$	(6,043)	$	109,634	$	(5,273)	$	(3,742)	$	94,612


		Nine Months Ended September 30, 2022
	Common Stock		Treasury Stock			Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total
		Shares	$		Shares	$		$		$		$		$
Balance, December 31, 2021		32,116,270	34		1,744,026	(5,248)		98,745		(11,575)		(33)		$	81,923
Exercise of stock options		442,450	1		—	—		1,160		—		—		1,161
Share-based compensation		246,627	—		—	—		2,838		—		—		2,838

ESPP issuance		101,454	—		—	—		521		—		—		521

Purchase of treasury stock		(40,931)	—		40,931	(294)		—		—		—		(294)



Net income		—	—		—	—		—		8,426		—		8,426
Foreign currency translation adjustment		—	—		—	—		—		—		(6,721)		(6,721)
Balance, September 30, 2022		32,865,870	$	35	1,784,957	$	(5,542)	$	103,264	$	(3,149)	$	(6,754)	$	87,854

Table of Contents

Luna Innovations Incorporated

Consolidated Statements of Cash Flows (Unaudited)

(in thousands, except share data)

Nine Months Ended
September 30,
2017 2016
(unaudited)
Cash flows provided by/(used in) operating activities
Net income/(loss) $ 14,179,576
$ (2,675,626 )
Adjustments to reconcile net income/(loss) to net cash used in operating activities

Depreciation and amortization 2,241,867
2,759,877

Share-based compensation 476,428
665,354

Bad debt expense 40,753
255,522

Loss on disposal of fixed assets 3,640
—

Gain on sale of discontinued operations (15,096,666 ) —

Change in assets and liabilities

Accounts receivable 2,127,794
(1,197,885 )
Inventory (2,251,236 ) 964,443

Other current assets 380,858
(381,632 )
Accounts payable and accrued expenses (1,581,608 ) (1,055,060 )
Deferred revenue 59,980
(120,871 )
Net cash provided by/(used in) operating activities 581,386
(785,878 )
Cash flows provided by/(used in) investing activities
Acquisition of property and equipment (893,698 ) (1,433,260 )
Intangible property costs (392,485 ) (317,287 )
Proceeds from sale of property and equipment 3,000
—

Proceeds from sales of discontinued operations 28,026,528
—

Net cash provided by/(used in) investing activities 26,743,345
(1,750,547 )
Cash flows provided by/(used in) financing activities
Payments on capital lease obligations (38,752 ) (44,404 )
Payments of debt obligations (1,375,000 ) (1,375,000 )
Repurchase of common stock (228,020 ) (325,060 )
Proceeds from the exercise of options 29,020
—

Net cash used in financing activities (1,612,752 ) (1,744,464 )
Net increase in cash and cash equivalents 25,711,979
(4,280,889 )
Cash and cash equivalents—beginning of period 12,802,458
17,464,040

Cash and cash equivalents—end of period $ 38,514,437
$ 13,183,151

Supplemental disclosure of cash flow information
Cash paid for interest $ 173,275
$ 239,347

Cash paid for income taxes $ 41,131
$ 203,305

Non-cash investing and financing activities
Dividend on preferred stock, 59,469 shares of common stock issuable for the nine months ended September 30, 2017 and 2016 $ 97,331
$ 74,731

Capital expenditures funded by capital lease borrowings $ —
$ 157,246


	Nine Months Ended September 30,
	2023		2022

Cash flows used in by operating activities
Net (loss)/income	$	(2,977)	$	8,426
Adjustments to reconcile net (loss)/income to net cash used in operating activities
Depreciation and amortization	4,092		3,993
Share-based compensation	3,219		3,204


Loss on disposal of property and equipment	281		—
Gain on sale of discontinued operations, net of tax	—		(10,921)
Deferred taxes	(998)		(3,374)
Change in assets and liabilities
Accounts receivable	(6,095)		(6,166)
Contract assets	1,145		(2,739)
Inventory	(6,520)		(6,662)
Other current assets	202		2,093
Other non-current assets	(121)		599
Accounts payable and accrued and other current liabilities	(479)		5,824
Contract liabilities	111		2,425
Other non-current liabilities	—		13
Net cash used in operating activities	(8,140)		(3,285)
Cash flows used in investing activities
Acquisition of property and equipment	(1,750)		(2,313)
Acquisition of intangible property	(95)		—

Proceeds from sale of discontinued operations	—		12,973
Acquisition of Luna Innovations Germany GmbH	—		(22,085)
Other	—		29
Net cash used in investing activities	(1,845)		(11,396)
Cash flows provided by financing activities
Payments on finance lease obligations	(37)		(36)
Proceeds from borrowings under debt obligations	10,400		22,150
Payments of debt obligations	(1,750)		(16,275)
Repurchase of common stock	(436)		(294)
Proceeds from ESPP	546		521
Proceeds from the exercise of stock options	1,272		1,160
Net cash provided by financing activities	9,995		7,226
Effect of exchange rate changes on cash and cash equivalents	(6)		(1,784)
Net increase/(decrease) in cash and cash equivalents	4		(9,239)
Cash and cash equivalents—beginning of period	6,024		17,128
Cash and cash equivalents—end of period	$	6,028	$	7,889
Supplemental disclosure of cash flow information
Cash paid for interest	$	1,590	$	209
Cash paid for income tax	$	3,206	$	220

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Luna Innovations Incorporated

Notes to Unaudited Consolidated Financial Statements


1.	~~Basis of Presentation and Significant Accounting Policies~~

1.Basis of Presentation and Significant Accounting Policies

Nature of Operations

Luna Innovations Incorporated (“we,” ~~“Luna Innovations”~~“our” or the “Company”), headquartered in Roanoke, Virginia, was incorporated in the Commonwealth of Virginia in 1990 and reincorporated in the State of Delaware in April 2003.

We are a leader in advanced optical technology, providing ~~unique capabilities in~~ high performance fiber optic test, measurement and control products for the telecommunications ~~industry,~~and photonics industries, and distributed fiber optic sensing solutions that measure, or "sense" the structures for industries ranging from aerospace, automotive, oil and gas, security and infrastructure. Our communications test and control products help customers test their fiber optic networks and assemblies with speed and precision in both lab and production environments. Our test and measurement products accelerate the development of high speed fiber optic components like photonic integrated circuits, coherent receivers and short-run fiber networks. Our distributed fiber optic sensing products help designers and manufacturers more efficiently develop new and innovative products by measuring stress, strain, and temperature at a high resolution for new designs or manufacturing processes. Our distributed fiber optic sensing products ensure the safety and structural integrity or operational health of critical assets in the field, by monitoring stress, strain, temperature and vibration in large civil and industrial infrastructure such as bridges, roads, pipelines and borders. We manufacture and sell "terahertz" (THz) products for layer thickness measurements for materials like plastics, rubber, and paint. Our THz products are used in the aerospace and ~~automotive industries,~~automotive/EV sector. We also provide applied research services, primarily under federally funded development programs, that leverage our sensing and custom optoelectronic components and subsystems. We are organized into two reportable segments, which work closely together to turn ideas into products: our Technology Development segment and our Products and Licensing segment. Our business model is designed to accelerate the process of bringing new and innovativeinstrumentation technologies to ~~market. We have a history~~meet the specific needs and applications of ~~net losses from operations beginning in 2005. We have historically managed~~ our ~~liquidity through cost reduction initiatives, debt financings, capital markets transactions and the sale of assets.~~customers.

Unaudited Interim Financial Information

The accompanying unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United ~~Stated~~States of America (“U.S. GAAP”) for interim financial statements and Article 10 of Regulation S-X of the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. The unaudited consolidated interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments, consisting of only normal recurring ~~accruals~~adjustments considered necessary to present fairly our financial position at September 30, ~~2017,~~2023, results of operations, comprehensive (loss)/income and changes in stockholders' equity for the three and nine months ended September 30, ~~2017~~2023 and ~~2016,~~2022, and cash flows for the nine months ended September 30, ~~2017~~2023 and ~~2016.~~2022. The results of operations for the three and nine months ended September 30, ~~2017,~~2023 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2017.~~2023. The consolidated balance sheet as of December 31, 2022 was derived from our audited consolidated financial statements.

The consolidated interim financial statements, including our significant accounting policies, should be read in conjunction with the audited ~~Consolidated Financial Statements~~consolidated financial statements and the notes thereto for the year ended December 31, ~~2016,~~2022, included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March ~~20, 2017.~~16, 2023.

Goodwill and Intangible Assets

Goodwill and intangible assets with indefinite lives are not amortized but are tested for impairment on an annual basis, as of October 1 of each year, or whenever events or changes in circumstances indicate that the carrying amount of these assets may be impaired. Purchased intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful lives. We analyze the reasonableness of the remaining useful life whenever events or circumstances indicate that the carrying amount may not be recoverable to determine whether the carrying value has been impaired.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between marketplace participants. Various valuation approaches can be used to determine fair value, each requiring different valuation inputs. The following hierarchy classifies the inputs used to determine fair value into three levels:

•Level 1—Quoted prices for identical instruments in active ~~markets~~markets.

Table of Contents

•Level 2—Quoted prices for similar instruments in active ~~markets,~~markets; quoted prices for identical or similar instruments in markets that are not ~~active,~~active; and model-derived valuations in which ~~all significant inputs and~~ significant value drivers are ~~observable in active markets~~observable.

•Level 3—Valuations derived from valuation techniques in which ~~one or more significant inputs or~~ significant value drivers are ~~unobservable~~unobservable.

The carrying values of cash and cash equivalents, accounts receivable, ~~and~~ accounts payable and accrued and other liabilities approximate fair value because of the short-term nature of these instruments. The carrying ~~value~~amount of ~~our debt approximates~~lease liabilities approximate fair value ~~as we~~because these financial instruments bear interest at rates that approximate current market rates for similar agreements with similar maturities and credit. We consider the terms of the PNC Bank, National Association debt facility, including itsfloating per annum interest rate ~~on our credit facilities with Silicon Valley Bank~~of the daily simple secured overnight financing rate ("~~SVB"~~SOFR"), plus an SOFR adjustment, plus a margin ranging from 1.75% to 2.75%, to be at market ~~for~~based upon similar ~~instruments. Certain non-financial~~instruments that would be available to us. The Company has certain assets and liabilities ~~are measured~~that have been recorded at fair value on a ~~nonrecurring~~non-recurring basis ~~in accordance with U.S. GAAP. This includes items such as non-financial assets~~following an acquisition.

Reportable Segments

We have one reportable segment that develops, manufactures and ~~liabilities initially measured at fair value in a business combination~~markets distributed fiber optic sensing products and ~~non-financial long-lived asset groups measured at fair value for an impairment assessment. In general, non-financial assets including intangible assets~~fiber optic communications test and ~~property and equipment are measured at fair value when there is an indication of impairment and are recorded at fair value only when any impairment is recognized.~~

control products.

Net ~~Loss~~Income/(Loss) Per Share

Basic per share data is computed by dividing our net ~~loss~~income/(loss) by the weighted average number of shares outstanding during the period. Diluted per share data is computed by dividing net ~~income, if applicable,~~income/(loss) by the weighted average shares outstanding during the period increased to include, if dilutive, the number of additional common share equivalents that would have been outstanding if potential shares of common stock had been issued using the treasury stock method. Diluted per share data would also include the potential common share equivalents relating to convertible securities by application of the if-converted method.

~~The effect~~For the three months ended September 30, 2023 and 2022, the effects of ~~5.0 million~~1,300,847 and 1,304,160 common stock equivalents ~~(which include outstanding warrants, preferred stock and stock options)~~ are included for the diluted per share data, ~~for the three months ended September 30, 2017. The effect of 5.6 million~~respectively. Stock options, restricted stock units and deferred stock units credited to our directors under our non-employee deferred compensation plan are included in our common stock equivalents are not included for the three months ended September 30, 2016 as they are anti-dilutive to earnings per share due to our net loss from continuing operations. The effect of 4.9 million and 5.7 million common stock equivalents are not included forequivalents. For the nine months ended September 30, ~~2017~~2023 and ~~2016, respectively,~~2022, all potentially dilutive securities for stock options and restricted stock units were excluded as ~~they~~their impact would be anti-dilutive.

The following shares could potentially dilute basic EPS in the future and have been excluded from the computation of diluted weighted average shares outstanding because the effect would be anti-dilutive:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2023	2022	2023	2022
Stock options	78,000	80,000	165,000	580,000
Restricted stock units	83,000	386,000	1,135,000	947,000

Foreign Currency

For our non-U.S. dollar functional currency subsidiaries, assets and liabilities are ~~considered anti-dilutive to earnings per share due to our net~~translated into U.S. dollars using fiscal period end exchange rates. Sales and expenses are translated at average monthly exchange rates. Foreign currency translation gains and losses are included as a component of accumulated other comprehensive loss within equity. Gains and losses resulting from ~~continuing operations.~~foreign currency transactions are included in earnings.

Recently Issued ~~Accounting~~ Pronouncements

~~Effective~~In June 2016, the FASB issued ASU 2016-13 Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments, which requires companies to measure financial assets at an amortized cost basis to be presented at the net amount expected to be collected. The new accounting rules eliminate the probable initial recognition threshold and, instead, reflect an entity's current estimate of all expected credit losses. ASU 2016-13 is applicable to our trade receivables and convertible note. This pronouncement was amended under ASU 2019-10 to allow an extension on the adoption date for entities that qualify as a small reporting company. We adopted ASU 2016-13, effective January 1, ~~2017, we adopted Accounting Standards Update ("ASU") No. 2016-09,~~ ~~Improvements to Employee Share-Based Payment Accountin~~g. These amendments apply to several aspects of accounting for share-based compensation including the recognition of excess tax benefits and deficiencies and their related presentation in the statement of cash flows as well as accounting for forfeitures.2023. The adoption of ASU ~~No. 2016-09 did not have a significant impact on our financial condition, results of operations or cash flows.~~

~~Effective January 1, 2017, we adopted ASU No. 2015-17,~~ ~~Balance Sheet Classification of Deferred Taxes~~, which simplifies the presentation of deferred taxes by requiring that deferred tax assets and liabilities be classified as noncurrent in any classified balance sheet rather than being separated into current and non-current amounts. The adoption of ASU No. 2015-172016-13 did not have a significant impact on our consolidated financial statements.

~~In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04,~~ ~~Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment~~. This update simplifies the subsequent measurement of goodwill. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for reporting periods beginning after December 15, 2019. We do not expect ASU 2017-04 will have a material impact on our financial statements.

~~In August 2016, the FASB issued ASU No. 2016-15,~~ ~~Statement of Cash Flows (Topic 230)~~, which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how cash receipts and cash payments are presented in the statement of cash flows. ASU 2016-15 is effective for public entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. The amendments should be applied retrospectively to all periods presented. We do not expect ASU 2016-15 will have a material impact on our financial statements.

Table of Contents

~~In April 2016, the FASB issued ASU 2016-10,~~ ~~Revenue from contracts with customers: Identifying Performance Obligations and Licensing~~, to clarify certain aspects of the existing standard specific to how an entity should recognize revenue to depict the transfer of promised goods or services to customers. Certain other ASUs have been issued specific to Topic 606 and our disclosure below includes our assessment of all ASUs specific to Topic 606 in the aggregate. In accordance with this update, we will adopt the requirements of the new standard effective January 1, 2018.

We are finalizing our assessment of the financial impact of Topic 606. To date we have reached the following conclusions specific to the impact of Topic 606. Contracts in our Technology Development segment primarily provide research services. We have concluded that revenue specific to this segment will not be materially impacted upon the adoption of Topic 606 as revenue will continue to be recognized over time using an input model. Contracts in our Products and Licensing segment generally provide for the following revenue sources: standard product sales, custom product development and sales, product rental, extended warranties, training/service, and certain royalties. We expect revenue for this segment to be recognized using either “point in time” or “over time” based on the revenue source. Based on our analysis to date we expect the pattern of recognition of the customized products to potentially change from “point in time” to “over time” upon the adoption of Topic 606. Our revenue recognized specific to customized products approximates $10 million annually. This change will result in the acceleration of revenue when compared to existing standards with the cumulative adjustment relating to contracts that are not complete as of December 31, 2017 recognized as an adjustment to opening retained earnings on January 1, 2018. We are continuing to assess the impact of this potential change, or other changes which may be subsequently identified, on our financial statements and current processes and controls. We intend to adopt the standard using the modified retrospective transition method. Under the modified retrospective approach, the new standard

will, for the period beginning January 1, 2018, apply to net contracts and those that were not completed as of January 1, 2018. For those contracts not completed as of January 1, 2018, this method will result in a cumulative catch-up adjustment to retained earnings. Prior periods will not be retrospectively adjusted, but we will maintain dual reporting for the year of initial application in order to disclose the effect on revenue of adopting the new guidance.

~~In February 2016, the FASB issued ASU No. 2016-02,~~ ~~Leases~~, which requires a lessee to recognize in its statement of financial position an asset and liability for most leases with a term greater than 12 months. Lessees should recognize a liability to make lease payments and a right-of-use asset representing the lessee's right to use the underlying asset for the lease term. The amendment is effective for fiscal years ending after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.

2. Discontinued Operations

~~On August 9, 2017,~~During the fourth quarter of 2022, we ~~completed~~recorded revenue and an unbilled receivable of $1.3 million related to our annual Incurred Cost Submission for the ~~sale~~year ended 2021 for projects from our Luna Labs business sold on March 7, 2022. As of ~~our high speed optical receivers ("HSOR") business, which was part of our Products and Licensing segment,~~June 30, 2023, we no longer believed we would be able to an unaffiliated third party for an initial purchase price of $33.5 million, of which $29.5 million in cash has been received, and $4.0 million was placed into escrow until December 15, 2018 for possible working capital adjustments tocollect the purchase price and potential satisfaction of certain post-closing indemnification obligations (the "Transaction"). The purchase price is subject to adjustment in the future based upon a determination of final working capital, as defined in the asset purchase agreement. The HSOR business was a componentmajority of the Luna Labs portion of the unbilled receivables and revised our estimated collection from $1.3 million to $0.1 million, resulting in a loss recorded in discontinuing operations of ~~Advanced Photonix, Inc., which we acquired in May 2015. As part~~$1.0 million, net of the Transaction, the buyer also hired approximately 49 of our employees who were engaged in the development, manufacture, and sale of HSOR products in addition to certain corporate administrative functions. The buyer will provide certain transition services to us with respect to infrastructure and administration for which we will pay $0.3 million per month for a period of five months, for a total of $1.5 million, following the date of the Transaction. We have recorded this obligation as a reduction of the value of the purchase price. In assessing the fair value of the services expected to be received by us versus those we expect to deliver to the buyer, we concluded that the transition service payments were more closely aligned with the fair value of the assets sold versus the services received and thus should be part of the consideration reconciliation versus operating activities. As of September 30, 2017, $0.6 million has been paid to the buyer and the remaining $0.9 million is included in accrued liabilities at September 30, 2017. Our HSOR business accounted for 8.2% of revenues and 10.1% of our cost of revenues fortax, during the three months ended June 30, 2023.

3.Intangible assets, net

Intangible assets, net at September 30, ~~2017,~~2023 and ~~16.1%~~December 31, 2022 consisted of ~~revenues~~the following:


	Estimated Life	September 30, 2023		December 31, 2022
(in thousands)
Patent costs	1 - 5 years	$	9,291	$	9,086
Developed technology	5 - 10 years	16,969		15,924
In-process research and development	N/A	1,478		2,631
Customer relationships	5 - 15 years	4,177		4,117
Trade names	3 - 5 years	866		880
Backlog	1 - 3 years	421		331
		33,202		32,969

Patent costs		(4,857)		(4,128)
Developed technology		(8,673)		(6,830)
In-process research and development		(1,540)		(1,763)
Customer relationships		(948)		(574)
Trade names		(620)		(586)
Backlog		(421)		(338)
Accumulated amortization		(17,059)		(14,219)
		$	16,143	$	18,750

Amortization expense for the three and ~~18.5%~~nine months ended September 30, 2023 was $0.9 million and $2.8 million, respectively. Estimated aggregate amortization, based on the net value of ~~our costs~~intangible assets at September 30, 2023, for each of ~~revenues for~~the next five years and beyond is as follows (in thousands):


Year Ending December 31,
2023 (remaining 3 months)	$	995
2024	3,576
2025	3,261
2026	3,163
2027	2,385
2028 & beyond	2,763
Total	$	16,143

Table of Contents

4.Goodwill

The change in the carrying value of goodwill during the nine months ended September 30, ~~2017.~~

We have reported the results of operations of our HSOR business as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax (benefit)/expense to discontinued operations based on the ratio of the discontinued business's loss/(income) before allocations.

~~The following table presents a summary of the transactions related to the sale.~~

September 30, 2017
(unaudited)
Sale price $ 33,500,000
Less: transition services payments (1,500,000 )
Adjusted purchase price 32,000,000

Assets held for sale (16,851,540 )
Liabilities held for sale 2,330,052
Transaction costs (873,473 )
Income tax expense (1,508,373 )
Gain on sale of discontinued operations $ 15,096,666

A~~ssets and liabilities held for sale as of December 31, 2016 were as follows:~~

December 31, 2016

Assets
Current assets:
Accounts receivable, net $ 4,028,713
Inventory 1,521,400
Prepaid expenses and other current assets 251,516
Total current assets 5,801,629
Property and equipment, net 3,298,151
Intangible assets, net 5,314,046
Goodwill 1,846,331
Other assets 50,754
Total non-current assets 10,509,282
Total assets held for sale $ 16,310,911
Liabilities
Current liabilities:
Accounts payable $ 1,511,450
Accrued liabilities 753,556
Deferred revenue 111,697
Total current liabilities 2,376,703
Long-term deferred rent 84,555
Total non-current liabilities 84,555
Total liabilities held for sale $ 2,461,258

~~The key components of income from discontinued operations were~~2023 was as follows:

Three Months Ended
September 30, Nine Months Ended September 30,
2017 2016 2017 2016
(unaudited) (unaudited)
Net revenues $ 1,041,310
$ 3,433,767
$ 6,356,237
$ 13,178,475
Cost of revenues 797,678
2,182,495
4,599,042
8,687,783
Operating expenses 447,854
1,342,117
2,750,951
3,901,685
Other expenses —
(1,608 ) —
(36,644 )
(Loss)/income before income taxes (204,222 ) (92,453 ) (993,756 ) 552,363
Allocated tax (benefit)/expense (349,515 ) (35,095 ) (349,515 ) 209,678
Operating income/(loss) from discontinued operations 145,293
(57,358 ) (644,241 ) 342,685
Gain on sale, net of related income taxes 15,096,666
—
15,096,666
—
Net income/(loss) from discontinued operations $ 15,241,959
$ (57,358 ) $ 14,452,425
$ 342,685

For the nine months ended September 30, 2017 and 2016, cash flows (used in)/provided by operating activities for discontinued operations were $(0.8) million and $0.2 million, respectively. For the nine months ended September 30, 2017 and 2016, cash flows provided by/(used in) investing activities for discontinued operations were $27.1 million and $(1.4) million, respectively.


3.(in thousands)	~~Inventory~~
Balance as of December 31, 2022		$	26,927
Foreign currency translation		(31)
Balance as of September 30, 2023		$	26,896

5.Inventory

Inventory consists of finished goods, work-in-process and raw materials valued at the lower of cost (determined on the first-in, first-out basis) or ~~market. We write down inventory for estimated obsolescence or unmarketable inventory in an amount~~

~~equal to the difference between the cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions.~~net realizable value.

Components of inventory were as follows:


	September 30, 2023		December 31, 2022
(in thousands)
Finished goods	$	11,236	$	9,930
Work-in-process	4,405		3,113
Raw materials	27,677		23,539
Total inventory	$	43,318	$	36,582

September 30,
2017 December 31,
2016
(unaudited)
Finished goods $ 2,234,828
$ 1,952,885
Work-in-process 844,083
714,867
Raw materials 4,221,124
4,181,083
Total inventory $ 7,300,035
$ 6,848,835

4.6. Accrued Liabilities

Accrued liabilities ~~at September 30, 2017 and December 31, 2016~~ consisted of the following:


	September 30, 2023		December 31, 2022
(in thousands)
Accrued compensation	$	8,344	$	8,962

Accrued professional fees	745		720
Accrued income tax	1,028		3,788
Warranty reserve	720		482
Accrued interest	110		64
Accrued liabilities - other	3,758		2,678
Total accrued and other current liabilities	$	14,705	$	16,694

7.Debt

Long-term debt consisted of the following:


	September 30, 2023		December 31, 2022
(in thousands)
Term Loan (net of debt issuance costs of $63 and $74, 7.90% and 6.65% at September 30, 2023 and December 31, 2022, respectively)	$	17,187	$	18,926
Revolving Loan (7.90% and 6.65% at September 30, 2023 and December 31, 2022)	14,700		4,300
	31,887		23,226
Less: Current portion of long-term debt obligations	(3,000)		(2,500)
Long-term debt obligations	$	28,887	$	20,726

Table of Contents

September 30, 2017 December 31, 2016
(unaudited)
Accrued compensation $ 4,377,850
$ 4,742,760

Income tax payable 1,027,687
—

Claims reserve 1,727,123
1,577,123

Transition services 900,000
—

Accrued sub-contracts 581,544
483,477

Accrued professional fees 70,308
67,719

Deferred rent 141,500
155,138

Royalties 263,625
345,895

Warranty reserve 212,849
185,125

Accrued liabilities - other 284,068
356,307

Total accrued liabilities $ 9,586,554
$ 7,913,544


5.	~~Debt~~

~~Silicon Valley~~PNC Bank Facility

~~We currently have~~On January 31, 2023, the Company entered into a Loan Modification Agreement (the "Third Amendment") in respect of the Loan Agreement and ~~Security~~previous amendments discussed hereafter to slightly modify its net leverage ratio and interest rate applicable margin. On June 21, 2022 (the “Effective Date”), the Company entered into a Loan Modification Agreement ~~with SVB~~ (the ~~"Credit Facility"~~“Second Amendment”) ~~under which,~~in respect of its Loan Agreement, dated as of December 1, 2020 (the “Original Loan Agreement” and as amended ~~on May 8, 2015,~~by that certain First Amendment to Loan Agreement, dated as of March 10, 2022, the Second Amendment, and the Third Amendment the “Loan Agreement”) with PNC Bank, National Association, as lender (the “Lender”) and certain of the Company’s domestic subsidiaries as guarantors, to, among other things, extend the maturity date of the Term Loan and Revolving Line (each as defined below) to June 21, 2027 and increase the total commitments to the Company.

The Loan Agreement provides a $15.0 million revolving credit facility (the “Revolving Line”) and a $20 million term loan facility (the “Term Loan”). On the Effective Date, we ~~have~~borrowed the full amount of the Term Loan from the Lender according to a term ~~loan with an original borrowing~~note (the “Term Note”), a portion of the proceeds of which were used to refinance the remaining principal amount of ~~$6.0~~the $12.5 million in term loans issued under the Original Loan Agreement, and the remainder of which were used to pay down approximately $13.7 million of the $15.0 million in revolving loans outstanding under the Revolving Line (the ~~“Original Term~~“Revolving Loan”) according to a revolving line of credit note (the “Revolving Line of Credit Note”). We may repay and reborrow advances under the Revolving Line from time to time according to the Revolving Line of Credit Note. The ~~Original~~unused Revolving Line totaled $0.3 million at September 30, 2023.

The Term Loan ~~is repayable in 48 monthly installments of $125,000, plus accrued interest payable monthly in arrears, and unless earlier terminated, is scheduled to mature in May 2020.~~matures on June 21, 2027. The ~~Original~~ Term Loan ~~carries~~amortizes at a ~~floating annual interest~~ rate equal to ~~SVB’s prime rate then~~10% for the first year, 15% for years two and three, 20% in ~~effect plus 2%. We may prepay amounts~~year four and 15% in year five, in each case payable on a quarterly basis. The remaining balance is due ~~under~~on maturity. Accrued interest is due and payable on the ~~Original~~first day of each month and the outstanding principal balance and any accrued but unpaid interest will be due and payable on June 21, 2027. The Term Loan ~~at any time, subject to an early termination fee of up to 2% of the amount of prepayment.~~

In September 2015, we entered into the Waiver and Seventh Loan Modification Agreement, which provided an additional $1 million of available financing for purchases of equipment through December 31, 2015, which we fully borrowed in December 2015 (the "Second Term Loan" and, together with the Original Term Loan, the "Term Loans"). The Second Term Loan also bears interest at a floating ~~prime~~per annum rate equal to the sum of (a) the daily simple secured overnight finance rate ("Daily Simple SOFR"), plus ~~2% and is~~(b) an SOFR adjustment of ten basis points (0.10%), plus (c) an applicable margin. The applicable margin ranges from 1.75% to ~~be repaid~~2.75% per annum, depending on our Net Leverage Ratio (as defined in ~~35 monthly installments of $27,778 plus accrued interest.~~the Loan Agreement). We may prepay the Term Loan without penalty or premium.

The ~~Credit Facility requires us~~Revolving Line expires on June 21, 2027. Borrowings under the Revolving Line bear interest at a floating per annum rate equal to ~~maintain a minimum cash balance~~the sum of ~~$4.0 million~~(a) the Daily Simple SOFR, plus (b) an SOFR adjustment of ten basis points (0.10%), plus (c) an applicable margin. The applicable margin ranges from 1.75% to 2.75% per annum, depending on our Net Leverage Ratio. Accrued interest is due and ~~to maintain at~~payable on the first day of each month ~~end a ratio of cash plus 60% of accounts receivable greater than or equal to 1.5 times~~and the outstanding principal balance and any accrued but unpaid interest is due and payable on June 21, 2027. The unused portion of the ~~Term Loans.~~ Revolving Line accrues a fee equal to 0.20% per annum multiplied by the quarterly average unused amount.

The ~~Credit Facility also requires us to observe~~Loan Agreement includes a number of affirmative and restrictive covenants applicable to us and our subsidiaries, including, among others, financial covenants regarding minimum net leverage and fixed charge coverage, affirmative covenants regarding delivery of financial statements, payment of taxes, and maintenance of government compliance, and restrictive covenants regarding dispositions of property, acquisitions, incurrence of additional ~~operational covenants, including protection~~indebtedness or liens, investments and ~~registration of intellectual property rights, and certain customary negative covenants. As of September 30, 2017, we~~transactions with affiliates. We are also restricted from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We were in compliance with ~~all~~these covenants ~~under the Credit Facility.~~

Amounts due under the Credit Facility are secured by substantially all of our assets, including intellectual property, personal property and bank accounts. In addition, the Credit Facility contains customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated debt documents, incorrectness of representations and warranties in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may declare due immediately all borrowings under the Credit Facility and foreclose on the collateral. Furthermore, an event of default under the Credit Facility would result in an increase in the interest rate on any amounts outstanding. As of September 30, 2017, there were no events of default on the Credit Facility.

The aggregate balance under the Term Loans at September 30, 2017 and December 31, 2016, was $2.9 million and $4.3 million, respectively. The effective rate of our Term Loan at September 30, 2017 was 6.25%.

~~The following table presents a summary of debt outstanding~~ as of September 30, ~~2017 and December 31, 2016:~~

2023.

September 30, 2017 December 31, 2016
(unaudited)
Silicon Valley Bank Term Loan $ 2,916,666
$ 4,291,666
Less: unamortized debt issuance costs 26,070
38,301
Less: current portion 1,833,333
1,833,333
Total long-term debt $ 1,057,263
$ 2,420,032

~~The schedule~~Upon the occurrence of ~~remaining principal payments~~certain events, including failure to satisfy our payment obligations under ~~our Term Loans as~~the Loan Agreement, failure to adhere to the financial covenants, the breach of ~~September 30, 2017 was as follows:~~

2017 $ 458,333
2018 1,833,333
2019 625,000
$ 2,916,666


6.	~~Capital Stock and Share-Based Compensation~~

We recognize share-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. For restricted stock awards and restricted stock units, we recognize expense based upon the pricecertain of our ~~underlying stock at~~other covenants under the ~~date of~~Loan Agreement, cross defaults to other indebtedness or material agreements, judgment defaults and defaults related to failure to maintain governmental approvals, the ~~grant. We~~Lender will have ~~elected~~the right, among other remedies, to ~~use~~declare all principal and interest immediately due and payable, and to exercise secured party remedies.

Table of Contents

Maturities on debt are as follows (in thousands):


Year Ending December 31,	Amount

2023 (remaining 3 months)	$	750
2024	3,000
2025	3,500
2026	4,000
2027	20,700
Total maturities	31,950
Less: deferred issuance costs	(63)
Total	$	31,887

8.Capital Stock and Share-Based Compensation

Stock Options

For the Black-Scholes-Merton option pricing model to value any option or warrant awards granted. We recognize share-based compensation for such awards on a straight-line basis over the requisite service period of the awards. The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. The expected lifethree and estimated post-employment termination behavior is based upon historical experience of homogeneous groups within our company. We also assume an expected dividend yield of zero for all periods, as we have never paid a dividend on our common stock and do not have any plans to do so in the future.

~~A summary of the stock option activity for the~~ nine months ended September 30, ~~2017 is presented below:~~

Options Outstanding Options Exercisable

Number of
Shares
Price per Share
Range
Weighted
Average
Exercise
Price

Aggregate
Intrinsic
Value (1)

Number of
Shares

Weighted
Average
Exercise
Price

Aggregate
Intrinsic
Value (1)
Balance, January 1, 2017 2,857,114
$0.61 - $6.83 $ 1.89
$ 107,063
2,367,630
$ 1.93
$ 101,071
Granted 80,000
$1.51 - $1.54 $ 1.53

Exercised (31,953 ) $0.82 - $1.38 $ 0.95

Canceled (170,590 ) $1.40 - $6.83 $ 2.27

Balance, September 30, 2017 2,734,571
$0.61 - $6.55 $ 1.87
$ 585,292
2,619,914
$ 1.88
$ 555,926


~~(1)~~	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of our common stock on the NASDAQ Capital Market, as applicable, on the respective dates.

At September 30, 2017, the outstanding stock options to purchase an aggregate of 2.7 million shares had a weighted-average remaining contractual term of 4.4 years, and the exercisable stock options to purchase an aggregate of 2.6 million shares had a weighted-average remaining contractual term of 4.3 years.

~~For the nine months ended September 30, 2017 and 2016~~2023, we recognized ~~$0.5 million~~$24.4 thousand and ~~$0.7 million~~$118.3 thousand, respectively, in share-based compensation expense ~~respectively,~~related to stock options, which is included in our selling, general and administrative expense in the accompanying consolidated ~~financial statements.~~statement of operations. Share-based compensation expense related to stock options for the three and nine months ended September 30, 2022 totaled $0.2 million and $0.6 million, respectively. We expect to recognize $0.1 million in share-based compensation expense over the weighted-average remaining service period of ~~1.8~~1.1 years for stock options outstanding as of September 30, ~~2017.~~

~~The following table summarizes the value of our unvested restricted stock awards:~~

Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Unvested Shares
Balance, January 1, 2017 829,998
$ 1.19
$ 988,763
Granted 428,865
$ 1.54
660,752
Vested (442,498 ) $ 1.20
(531,853 )
Repurchased —
$ —
—
Forfeitures (51,667 ) $ 1.14
(58,917 )
Balance, September 30, 2017 764,698
$ 1.38
$ 1,058,745

2023.

Restricted Stock Units

We issue restricted stock units ("RSUs"), to our non-employee directors for service on our board of directors. Under our non-employee director compensation policy, continuing non-employee directors receive an annual RSU grant at the time of our annual meeting of stockholders, which grant vests on the earlier of the one year anniversary of the grant or the following annual meeting of stockholders. Under our non-employee director deferred compensation plan, as amended (the "NEDCP") non-employee directors may also elect to receive their annual cash retainers for board and committee service in RSUs which are issued quarterly and vest immediately upon their issuance, subject to deferred settlement in accordance with the NEDCP.

~~The following is a summary of our RSU activity for the nine months ended September 30, 2017:~~

Number of RSUs Intrinsic Value
Issued Unvested Weighted Average Grant Date Fair Value per Share Outstanding Unvested
Balance, January 1, 2017 393,012
—
$1.37 $ 577,728
$ —
  Granted 55,748
—
$1.57
  Vested —
—
$0.00
  Forfeitures —
—
$0.00
  Converted —
—
$0.00
Balance, September 30, 2017 448,760
—
$1.39 $ 758,404
$ —

~~The following details our equity transactions during the nine months ended September 30, 2017:~~

Preferred Stock Common Stock Treasury Stock
Additional
Paid-in
Capital
Shares $ Shares $ Shares $ $
Balance, January 1, 2017 1,321,514
1,322
27,541,277
28,600
446,827
(517,987 ) 82,451,958
Exercise of stock options —
—
31,953
32
—
—
819
Share-based compensation —
—
299,000
299
—
—
476,128
Non-cash compensation —
—
135,497
136
—
—
178,035
Stock dividends to Carilion Clinic⁽¹⁾
—
—
—
59
—
—
97,271
Forfeitures of restricted stock grants —
—
(51,667 ) (52 ) —
—
—
Repurchase of common stock —
—
(141,000 ) —
141,000
(228,020 ) 52
Balance, September 30, 2017 1,321,514
1,322
27,815,060
29,074
587,827
(746,007 ) 83,204,263

~~(1)~~

The stock dividends payable in connection with Carilion Clinic’s Series A Preferred Stock will be issued subsequent to September 30, 2017. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2017, the Series A Preferred Stock issued to Carilion has accrued $1,110,773 in dividends. The accrued and unpaid dividends as of September 30, 2017 will be paid by the issuance of 611,870 shares of our common stock upon Carilion’s written request.

~~Stock Repurchase Program~~

In May 2016, our board of directors authorized us to repurchase up to $2.0 million of our common stock through May 31, 2017. As of May 31, 2017, we had repurchased a total of 205,500 shares for an aggregate purchase price of $0.2 million under this stock repurchase program, after which this stock repurchase program expired.

In September 2017, our board of directors re-instituted the stock repurchase program and authorized us to repurchase up to $2.0 million of our common stock through September 19, 2018. Our stock repurchase program does not obligate us to acquire any specific number of shares. Under the program, shares may be repurchased in privately negotiated or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. As of September 30, 2017, we had repurchased a total of 50,100 shares for an aggregate purchase price of $0.1 million under this stock repurchase program. We currently maintain all repurchased shares under these stock repurchase programs as treasury stock.


7.	~~Operating Segments~~

~~Our operations are divided into two operating segments—“Technology Development” and “Products and Licensing”.~~

The Technology Development segment provides applied research to customers in our areas of focus. Our engineers and scientists collaborate with our network of government, academic and industry experts to identify technologies and ideas with promising market potential. We then compete to win fee-for-service contracts from government agencies and industrial customers who seek innovative solutions to practical problems that require new technology. The Technology Development segment derives its revenues primarily from services.

~~The Products and Licensing segment derives its revenues from product sales, funded product development and technology licenses.~~

Through September 30, 2017, our Chief Executive Officer and his direct reports collectively represented our chief operating decision makers, and they evaluated segment performance based primarily on revenues and operating income or loss. The accounting policies of our segments are the same as those described in the summary of significant accounting policies (see Note 1 to our Financial Statements, “Organization and Summary of Significant Accounting Policies,” presented in our Annual Report on Form 10-K as filed with the SEC on March 20, 2017).

~~The table below presents revenues and operating income/(loss) for reportable segments:~~

Products and licensing depreciation includes amounts from discontinued operations of $0.1 million and $0.2 million for the three months ended September 30, 2017 and 2016, respectively. Products and licensing amortization includes amounts from discontinued operations of $0.1 million and $0.4 million for the three months ended September 30, 2017 and 2016, respectively. Products and licensing depreciation includes amounts from discontinued operations of $0.4 million and $0.5 million for the nine months ended September 30, 2017 and 2016, respectively. Products and licensing amortization includes amounts from discontinued operations of $0.9 million and $1.2 million for the nine months ended September 30, 2017 and 2016, respectively.

~~The table below presents assets for reportable segments:~~

September 30,
2017 December 31,
2016
(unaudited)
Total segment assets:
Technology development $ 30,738,481
$ 16,923,090
Products and licensing 35,870,670
38,073,883
Total assets $ 66,609,151
$ 54,996,973
Property plant and equipment, and intangible assets, technology development $ 2,427,556
$ 2,602,803
Property plant and equipment, and intangible assets, products and licensing $ 4,484,498
$ 4,749,144

There are no material inter-segment revenues for any period presented. Total assets for September 30, 2017 include proceeds from the sale of HSOR in the amount of $33.5 million (which includes a long term receivable of $4.0 million) allocated evenly between the two segments. For December 31, 2016, the products and licensing segment assets include assets held for sale in the amount of $16.3 million. Property plant and equipment, and intangible assets excludes HSOR amounts for September 30, 2017 and December 31, 2016.

The U.S. government accounted for 45% and 39% of total consolidated revenues for the three months ended September 30, 2017 and 2016, respectively, and for 45% and 42% of total consolidated revenues for the nine months ended September 30, 2017 and 2016, respectively.

International revenues (customers outside the United States) accounted for 19% and 15% of total consolidated revenues for the three months ended September 30, 2017 and 2016, respectively, and 20% and 18% of the total consolidated revenues for the nine months ended September 30, 2017 and 2016, respectively. No single country, outside of the United States, represented more than 10% of total revenues inDuring the three and nine months ended September 30, ~~2017~~2023, we granted 85,740 and ~~2016.~~388,869 time-based restricted stock units ("RSUs"), respectively. During the three and nine months ended September 30, 2022, we granted 190,000 and 823,842 time-based RSUs, respectively. The general terms of the RSUs are similar to awards previously granted by us. The weighted average fair value of the time-based RSUs granted during the three and nine months ended September 30, 2023 was $8.87 and $8.37 per share, respectively. The fair value of each RSU was determined based on the market price of our stock on the date of grant.

In addition, pursuant to our Deferred Compensation Plan, non-employee directors can elect to defer the receipt of some or all of the equity compensation that they receive for board and committee service. During the three and nine months ended September 30, 2023, we granted 7,348 and 65,284.76 RSUs, respectively, pursuant to the Deferred Compensation Plan. During the three and nine months ended September 30, 2022, we granted 14,299 and 112,560 RSUs, respectively, pursuant to the Deferred Compensation Plan. The general terms of these RSUs are similar to awards previously granted by us. The weighted average fair value of these RSUs granted during the three and nine months ended September 30, 2023, was $9.05 and $8.65 per share, respectively. The fair value of each RSU was determined based on the market price of our stock on the date of grant.

For the three and nine months ended September 30, 2023, we recognized $0.9 million and $2.8 million, respectively, in share-based compensation expense related to RSUs, which is included in our selling, general and administrative expense in the accompanying consolidated statement of operations. Share-based compensation related to RSUs for the three and nine months ended September 30, 2022 totaled $0.6 million and $1.8 million, respectively. We expect to recognize $5.8 million in share-based compensation expense over the weighted-average remaining service period of 1.2 years for RSUs outstanding as of September 30, 2023.

Employee Stock Purchase Plan ("ESPP")

For each of the three and nine months ended September 30, 2023, we recognized $0.1 million and $0.3 million, respectively, in share-based compensation expense related to the ESPP, which is included in our selling, general and administrative expense in the accompanying consolidated statement of operations. Share-based compensation related to the ESPP for the three and nine months ended September 30, 2022 totaled $0.1 million and $0.2 million, respectively.

Table of Contents


8.	~~Contingencies and Guarantees~~

9.Revenue Recognition

Disaggregation of Revenue

We disaggregate our revenue from contracts with customers by geographic locations, customer type, contract type, timing of recognition, and major categories, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. We disaggregate revenue on the basis of where the physical goods are shipped. We also classify revenue by the customer type of entity for which it does business, which is an indicator of the diversity of our client base. We attribute revenue generated from being a subcontractor to a commercial company as government revenue when the ultimate client is a government agency or department. Disaggregation by contract mix provides insight in terms of the degree of performance risk that we have assumed. Fixed-price contracts are considered to provide the highest amount of performance risk as we are required to deliver a scope of work or level of effort for a negotiated fixed price. Cost-based contracts are considered to provide the lowest amount of performance risk since we are generally reimbursed for all contract costs incurred in performance of contract deliverables with only the amount of incentive or award fees (if applicable) dependent on the achievement of negotiated performance requirements. By classifying revenue by major product and service, we attribute revenue from a client to the major product or service that we believe to be the client's primary market.

Table of Contents

The details are listed in the table below for the three and nine months ended September 30, 2023 and 2022:


		Three Months Ended September 30,				Nine Months Ended September 30,

		2023		2022		2023		2022
(in thousands)		(unaudited)				(unaudited)
Total Revenue by Geographic Location
	United States	$	10,238	$	12,597	36,280		$	33,361
	Asia	11,388		7,248		20,769		16,265
	Europe	6,266		8,300		19,566		20,765
	Canada, Central and South America	1,859		661		5,681		6,846
	All Others	952		347		2,616		558
	Total	$	30,703	$	29,153	$	84,912	$	77,795

Total Revenue by Major Customer Type
	Sales to the U.S. government	$	1,982	$	2,604	$	5,207	$	6,394
	U.S. direct commercial sales and other	8,257		9,993		31,074		26,967
	Foreign commercial sales & other	20,464		16,556		48,631		44,434
	Total	$	30,703	$	29,153	$	84,912	$	77,795

Total Revenue by Contract Type
	Fixed-price contracts	$	30,234	$	28,202	$	82,757	$	75,556
	Cost-type contracts	469		951		2,155		2,239
	Total	$	30,703	$	29,153	$	84,912	$	77,795

Total Revenue by Timing of Recognition
	Goods transferred at a point in time	$	27,921	$	25,114	75,761		$	66,608
	Goods/services transferred over time	2,782		4,039		9,151		11,187
	Total	$	30,703	$	29,153	$	84,912	$	77,795

Total Revenue by Major Products/Services
	Technology development	$	1,253	$	2,062	4,381		$	5,198
	Test, measurement and sensing systems	29,217		26,809		79,783		70,927
	Other	233		282		748		1,670
	Total	$	30,703	$	29,153	$	84,912	$	77,795

Contract Balances

Our contract assets consist of unbilled amounts for research contracts as well as custom product contracts. Contract liabilities include excess billings, and customer deposits. During the three and nine months ended September 30, 2023, we recognized $0.3 million and $2.9 million of revenue, respectively, that was included in contract liabilities as of December 31, 2022.

Table of Contents

The following table shows the components of our contract balances as of September 30, 2023 and December 31, 2022:


	September 30, 2023		December 31, 2022
(in thousands)
Contract assets	$	7,324	$	7,691
Contract liabilities	4,619		4,089
Net contract assets	$	2,705	$	3,602

Performance Obligations

Unfulfilled performance obligations represent amounts expected to be earned on executed contracts. Indefinite delivery and quantity contracts and unexercised options are not reported in total unfulfilled performance obligations. Unfulfilled performance obligations include funded obligations, which is the amount for which money has been directly authorized by the U.S. government and for which a purchase order has been received by a commercial customer, and unfunded obligations represent firm orders for which funding has not yet been appropriated. The approximate value of our unfulfilled performance obligations was $49.0 million at September 30, 2023. We expect to satisfy 41% of the performance obligations in 2023, 55% in 2024 and the remainder by 2028.

10.Income Taxes

Our provision for income taxes is based upon the estimated annual effective tax rate for the year applied to the current period income plus the tax effect of any significant or unusual items, discrete events or changes in tax law. Fluctuations in the distribution of pre-tax income among our operating subsidiaries can lead to fluctuations of the effective tax rate in the consolidated financial statements. We and our subsidiaries file U.S. federal income tax returns and income tax returns in various state, local, and foreign jurisdictions.

For the nine months ended September 30, 2023, our effective income tax rate was 27.2% compared to 14.5% for the nine months ended September 30, 2022. Historically, our tax rate can vary significantly from the federal statutory rate of 21% due to losses generated in jurisdictions where the benefit is not expected to be recognized partially offset by favorable impacts from stock award vesting and exercises, foreign-derived intangible income deduction and research and development tax credits.

11.Commitments and Contingencies

We are from time to time involved in certain legal proceedings in the ordinary course of conducting our business. While the ultimate liability pursuant to these actions cannot currently be determined, we believe it is not reasonably possible that these legal proceedings will have a material adverse effect on our financial position or results of operations.

~~In September 2014, we received a preliminary audit report from the Defense Contract Audit Agency (the "DCAA"), with respect to our 2007 incurred cost submission and questioning $0.8~~We executed multiple non-cancelable purchase orders totaling $3.1 million of claimed costs that the DCAA believes are expressly unallowable under the Federal Acquisition Regulations and, therefore, subject to potential penalty. In June 2015, we received from the Defense Contract Management Agency ("DCMA") a final determination and demand for payment of penalties, interest, and over billing in the ~~aggregate amount~~second quarter of ~~$1.1 million. In July 2015, we filed an appeal with~~2022, $4.6 million in the ~~Armed Services Board~~fourth quarter of ~~Contract Appeals ("ABSCA"). In January 2017, a hearing was held before~~2022, $0.6 million in the ~~ASBCA. No ruling has yet been issued with respect to our appeal. In April 2017, we made a settlement offer~~first quarter of ~~$150,000 to the DCMA,~~2023, and ~~we have accrued that amount~~$2.7 million in ~~our financial statements as of September 30, 2017. The DCMA notified us in May 2017 that it has declined our settlement offer. The appeals process remains ongoing.~~

In the third quarter of ~~2016 we executed two non-cancelable purchase orders totaling $1.4 million~~2023 for multiple shipments of tunable lasers to be delivered over ~~an 18-month~~a 11-21 month period. At September 30, ~~2017,~~2023, approximately ~~$0.3~~$7.9 million of ~~this commitment~~non-cancelable purchase order commitments remained and isare expected to be delivered by ~~February 28, 2018.~~March 3, 2025.

We have entered into indemnification agreements with our officers and directors, to the extent permitted by law, pursuant to which we have agreed to reimburse the officers and directors for legal expenses in the event of litigation and regulatory matters. The terms of these indemnification agreements provide for no limitation to the maximum potential future payments. We have a directors and officers insurance policy that may, in certain instances, mitigate the potential liability and payments.

Table of Contents



ITEM 2.			MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Quantitative and Qualitative Disclosures About Market Risk” under Items 2 and 3, respectively, of Part I of this report, and the section entitled “Risk Factors” under Item 1A of Part II of this report, may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of these statutes, including those relating to future events or our future financial performance. In some cases, you can identify these forward looking statements by words such as “intends,” “will,” “plans,” “anticipates,” “expects,” “may,” “might,” “estimates,” “believes,” “should,” “projects,” “predicts,” “potential” or “continue,” or the negative of those words and other comparable words, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. Similarly, statements that describe our business strategy, goals, prospects, opportunities, outlook, objectives, plans or intentions are also forward-looking statements. These statements are only predictions and may relate to, but are not limited to, expectations of future operating results or financial performance, capital expenditures, introduction of new products, regulatory compliance and plans for growth and future operations, the potential benefits of past acquisitions and dispositions, as well as assumptions relating to the foregoing.

These statements are based on current expectations and assumptions regarding future events and business performance and involve known and unknown risks, uncertainties and other factors that may cause actual events or results to be materially different from any future events or results expressed or implied by these statements. These factors include those set forth in the following discussion and within Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q and elsewhere within this report.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this report. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” and elsewhere in this report.

Overview of Our Business

Our communications test and control products help customers test their fiber optic networks and assemblies with speed and precision in both lab and production environments. Our test and measurement products accelerate the ~~aerospace~~development of high speed fiber optic components like photonic integrated circuits ("PICs"), coherent receivers and ~~automotive industries, and custom optoelectronic components and subsystems.~~short-run fiber networks. Our distributed fiber optic sensing products ~~provide critical~~help designers and manufacturers more efficiently develop new and innovative products by measuring stress, strain, and temperature ~~information to designers~~at a high resolution for new designs or manufacturing processes. In addition, our distributed fiber optic sensing products ensure the safety and ~~manufacturers working with advanced materials.~~structural integrity or operational health of critical assets in the field, by monitoring stress, strain, temperature and vibration in large civil and industrial infrastructure such as bridges, roads, pipelines and borders. We manufacture and sell "terahertz" (THz) products for layer thickness measurements for materials like plastics, rubber and paint. Our ~~custom optoelectronic~~THz products are ~~sold to scientific instrumentation manufacturers for various applications such as metrology, missile guidance, flame monitoring,~~used in the aerospace and ~~temperature sensing. In addition, we~~automotive/EV sectors. We also provide applied research services, ~~typically~~primarily under ~~research~~federally funded development programs, ~~funded by the U.S. government, in areas of advanced materials,~~that leverage our sensing and ~~healthcare applications. Our business model is designed to accelerate the process of bringing new and innovative products to market. We use our in-house technical expertise across a range of~~instrumentation technologies to ~~perform applied research services for companies~~meet the specific needs and ~~for government funded projects. We continue to invest in product development and commercialization, which~~applications of our customers.

As we ~~anticipate will lead to increased product sales growth.~~

We are organized into two main business segments, the Products and Licensing segment and the Technology Development segment. Our Products and Licensing segment develops, manufactures and markets fiber optic sensing products, as well as test & measurement products, and also conducts applied research in the fiber optic sensing area for both corporate and government customers. We are continuing to develop and commercialize new products, our revenue will reflect a broader and more diversified mix of products. Our key initiative for long term growth is to become a leading provider of fiber optic ~~technology~~communications test, measurement, control and sensing equipment. Recent acquisitions have added strategic technologies and products that complement our existing suite of sensing products and provided for expansion into high-growth markets such as security and perimeter detection, smart infrastructure monitoring and oil and gas. Our products have historically been strong in long-range, discrete sensing and short range, fully distributed sensing which are best when specific, known locations need to be monitored. Additional product offerings from these strategic acquisitions have helped us fill a gap for long range, fully distributed acoustic, temperature and strain measurement, which is best for applications where signals can occur anywhere along the length of the sensor.

Table of Contents

We may incur increasing expenses as we seek to expand our business, including expenses for research and ~~temperature sensing applications for the aerospace, automotive,~~development, sales and ~~energy industries. Our Products~~marketing and ~~Licensing segment revenues represented 61%~~manufacturing capabilities. We may continue to grow our business in part through acquisitions of additional companies and ~~63%~~complementary technologies, which could cause us to incur transaction expenses, amortization or write-offs of ~~our total revenues for the three months ended September 30, 2017~~intangible assets and ~~2016, respectively,~~goodwill and ~~59% and 61% of our total revenues for the nine months ended September 30, 2017 and 2016, respectively. The change in revenue mix was primarily~~other acquisition-related expenses. As a result, ~~of continued growth of our Technology Development business segment. The approximate value of our Products~~we may incur net losses in future periods, and ~~Licensing segment backlog was $6.9 million at September 30, 2017 and $7.2 million at December 31, 2016.~~these losses could be substantial.

The Technology Development segment performs applied research principally in the areas of sensing and instrumentation, advanced materials and health sciences. This segment comprised 39% and 37% of total revenues for the three months ended September 30, 2017 and 2016, respectively, and 41% and 39% of our total revenues for the nine months ended September 30, 2017 and 2016, respectively. Most of the government funding for our Technology Development segment is derived from the Small Business Innovation Research ("SBIR") program coordinated by the U.S. Small Business Administration ("SBA"). The Technology Development segment revenues have historically accounted for a large portion of total revenues, and we expect that they will continue to represent a significant portion of total revenues for the foreseeable future. The Technology Development segment revenues were $4.6 million and $4.1 million for the three months ended September 30, 2017 and 2016, respectively, and $13.4 million and $11.8 million for the nine months ended September 30, 2017 and 2016, respectively. Within the Technology Development segment, we have historically had a backlog of contracts for which work has been scheduled, but for which a specified portion of work has not yet been completed. Backlog

We define backlog as the dollar amount of obligations payable to us under negotiated contracts upon completion of a specified portion of work that has not yet been completed, exclusive of ~~revenues~~revenue previously recognized for work already performed under these contracts, if any. Total backlog includes funded backlog, which is the amount for which money has been directly authorized by the U.S. government ~~and~~or for which a purchase order has been received byfrom a commercial customer, and unfunded backlog, ~~representing~~which represents firm orders for which funding has not yet been appropriated. ~~Indefinite delivery~~Our backlog of purchase orders received for which the related goods have not been shipped or recognized as revenue was $49.0 million and ~~quantity contracts and unexercised options are not reported in total backlog. The approximate value of our Technology Development segment backlog was $27.3~~$52.9 million at September 30, ~~2017~~2023 and ~~$17.6 million at~~ December 31, ~~2016.~~

Revenues from product sales have historically been mostly derived from the sales of our optoelectronic components and from the sales of sensing systems and products that make use of light-transmitting optical fibers, or fiber optics. We continue to invest in product development and commercialization, which we anticipate will lead to increased product sales growth. Although we have been successful in licensing certain technology in past years, we do not expect license revenues to represent a significant portion of revenues in the near term. Over time, however, we do intend to gradually increase such revenues. In the near term, we expect revenues from product sales and product development to be primarily in areas associated with our fiber optic instrumentation, test & measurement and sensing platforms. In the long term, we expect that revenues from product sales will represent a larger portion of our total revenues and, as we develop and commercialize new products, we expect these revenues will reflect a broader and more diversified mix of products.

We may also grow our business in part through acquisitions of additional companies and complementary technologies, which could cause us to incur transaction expenses, amortization or write-offs of intangible assets and other acquisition-related expenses.

Reductions in government spending may impact the availability of new program awards in the future. For example, the Budget Control Act commits the U.S. government to reduce the federal deficit by $1.2 trillion over ten years through a combination of automatic, across-the-board spending cuts and caps on discretionary spending, or sequestration. Automatic across-the-board cuts required by sequestration could have a material adverse effect on our Technology Development segment revenues and, consequently, our results of operations. While the exact manner in which sequestration will impact our business is unclear, funding for programs in which we participate could be reduced, delayed or canceled. Our ability to obtain new contract awards also could be negatively affected.

~~Recent Developments~~

On August 9, 2017, we sold our assets associated with the high speed optical receiver ("HSOR") business to a third party, for total cash consideration of $33.5 million, including $29.5 million received at closing and $4.0 million placed into escrow until December 15, 2018 for possible working capital adjustments to the purchase price and potential satisfaction of certain post-closing indemnification obligations. As part of the transaction, the buyer also hired 49 of our employees who were engaged in the development, manufacture, and sale of HSOR products in addition to certain corporate administrative functions. The buyer will provide certain transition services to us with respect to infrastructure and administration for which we will pay $0.3 million per month for a period of five months following the date of the transaction. We have recorded this obligation as a reduction of the value of the purchase price. As of September 30, 2017, $0.6 million has been paid to the buyer and the remaining $0.9 million is included in our accrued liabilities.

Our revenues recognized related to the HSOR business were $1.0 million and $3.4 million for the three months ended September 30, 2017 and 2016, respectively, and $6.4 million and $13.2 million for the nine months ended September 30, 2017 and 2016,2022, respectively.

Our sale of the HSOR business has significantly increased our capital resources, and we currently intend to use a portion of the proceeds from the sale to invest in expanding our fiber optic sensing business. However, the sale of the HSOR business is expected to result in lower revenues, primarily from reduced product sales, than we have experienced in prior periods until, if

~~ever, we can increase revenues from our remaining businesses significantly. As a result, we may incur greater net losses and reduced cash flows from operations than we have in recent periods.~~

Description of ~~Revenues,~~Revenue, Costs and Expenses

~~Revenues~~Revenue

We generate ~~revenues~~revenue from ~~technology development,~~ product sales and commercial product development and, licensing activities. We derive Technology Development segment revenues from providing research and development services to third parties, including government entities, academic institutions and corporations, and from achieving milestones established by some of these contracts and in collaboration agreements. In general, we complete contracted research over periods ranging from six months to three years, and recognize these revenues over the life of the contract as costs are incurred. The Technology Development segment revenues represented 39% and 37% of total revenues for the three months ended September 30, 2017 and 2016, respectively, and 41% and 39% of our total revenues for the nine months ended September 30, 2017 and 2016, respectively.

~~The Products and Licensing segment revenues reflect amounts that we receive from sales of our products or development of products for third parties and,~~ to a lesser ~~extent,~~degree, fees paid to us in connection with licenses or sub-licenses of certain patents and other intellectual ~~property,~~property. We also generate revenue from providing research and ~~represented 61%~~development services to third parties, including government entities and 63% of our total revenues for the three months ended September 30, 2017 and 2016, respectively, and 59% and 61% of our total revenues for the nine months ended September 30, 2017 and 2016, respectively. Product and licensing revenues decreased as a percentage of our total revenues primarily a result of continued growth of our Technology Development business segment during the three and nine months ended September 30, 2017 compared to the three and nine months ended September 30, 2016.corporations.

Cost of ~~Revenues~~Revenue

Cost of ~~revenues~~revenue associated with our ~~Technology Development segment revenues~~product revenue consists of ~~costs associated with performing the related research activities including direct labor, amounts paid to subcontractors and overhead allocated to Technology Development segment activities.~~

~~Cost of revenues associated with our Products and Licensing segment revenues consists of license fees for use of certain technologies,~~ product manufacturing costs including all direct material and direct labor costs, amounts paid to our contract manufacturers, manufacturing, shipping and handling, provisions for product warranties, license fees for use of certain technologies and inventory obsolescence as well as overhead allocated to each of these activities.

Cost of revenue associated with our contract research revenue consists of costs associated with performing the related research activities including direct labor, amounts paid to subcontractors and allocate overhead.

Operating Expense

Operating expense consists of selling, general and administrative expenses, as well as expenses related to research, development and engineering, depreciation of fixed assets, ~~and~~ amortization of intangible ~~assets.~~assets and costs related to merger and acquisition activities. These expenses also include compensation for employees in executive and operational functions including certain non-cash charges related to expenses from ~~option grants,~~equity awards, facilities costs, professional fees, salaries, commissions, travel expense and related benefits of personnel engaged in sales, ~~product management~~marketing and ~~marketing~~administrative activities, costs of marketing programs and promotional materials, salaries, bonuses and related benefits of personnel engaged in our own research and development, ~~beyond the scope and activities of our Technology Development segment,~~ product development activities not provided under contracts with third parties, and overhead costs related to these activities.

Interest Expense

Interest expense is composed of interest paid under our term and revolving loans as well as interest accrued on our ~~capital~~finance lease obligations.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the amounts reported in our financial statements and the accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or judgments.

Our critical accounting policies are described in the Management’s Discussion and Analysis section and the notes to our audited consolidated financial statements previously included in our Annual Report on Form 10-K for the year ended December 31, ~~2016,~~2022, as filed with the Securities and Exchange Commission ("SEC") on March ~~20, 2017. Effective January 1, 2017, we adopted Accounting Standards Update ("ASU") No. 2016-09,~~ ~~Improvements to Employee Share-Based Payment Accounting~~. The amendments apply to several aspects of accounting for share-based compensation including the recognition of excess tax benefits and deficiencies and their related presentation in the statement of cash flows as well as accounting for forfeitures. The adoption of ASU No. 2016-09 did not have a significant impact on our financial condition, results of operations or cash flows. There have been no other material changes to the description of our critical accounting policies as described in our Form 10-K as filed with the SEC on March 20, 2017.16, 2023.

Table of Contents

Results of Operations

Three Months Ended September 30, ~~2017~~2023 Compared to Three Months Ended September 30, ~~2016~~2022

~~Revenues~~Revenue

Three Months Ended September 30,
2017 2016 $ Difference % Difference
Revenues:
Technology development $ 4,590,054
$ 4,118,245
$ 471,809
11 %
Products and licensing 7,052,094
7,066,908
(14,814 ) 0 %
Total revenues $ 11,642,148
$ 11,185,153
$ 456,995
4 %

~~Revenues from our Technology Development segment~~Revenue for the three months ended September 30, ~~2017~~2023 increased ~~$0.5~~$1.6 million, or ~~11%~~5%, to ~~$4.6~~$30.7 million compared to ~~$4.1~~$29.2 million for the three months ended September 30, ~~2016.~~2022. The increase in ~~Technology Development segment revenues continues a growth trend experienced throughout 2016 and into 2017 largely driven by successes in Phase 2 SBIR awards. The increase~~revenue for the three months ended September 30, ~~2017~~2023, compared to the three months ended September 30, ~~2016~~2022, was ~~realized~~ primarily ~~in our intelligent systems research group. As Phase 2 contracts generally have a performance period of a year or more, we currently expect revenues~~due to ~~remain at a similar level for the near term.~~

~~Our Products and Licensing segment included revenues from sales of test & measurement systems, primarily representing~~strong growth in sales of our ~~ODiSI, Optical Vector Analyzer, and Optical Backscatter Reflectometer platforms, optical components and sub-assemblies and~~communications test products partially offset by a slight decline in sales of ~~Terahertz~~our sensing ~~systems. Products~~products.

Cost of Revenue and ~~Licensing segment revenues remained substantially unchanged at $7.1~~Gross Profit

Cost of revenue increasedby $0.8 million, or 7%, to $13.1 million for the three months ended September 30, ~~2017 and 2016.~~

~~Cost of Revenues and Gross Profit~~

Three Months Ended September 30,
2017 2016 $ Difference % Difference
Cost of revenues:
Technology development $ 3,491,840
$ 3,068,360
$ 423,480
14 %
Products and licensing 3,617,547
3,758,765
(141,218 ) (4 )%
Total cost of revenues 7,109,387
6,827,125
282,262
4 %
Gross profit $ 4,532,761
$ 4,358,028
$ 174,733
4 %

~~The cost of Technology Development segment revenues~~2023, compared to $12.2 million for the three months ended September 30, ~~2017~~2022. The increase in cost of revenue slightly outpaced our sales growth. Our overall gross margin for the three months ended September 30, 2023 was 57%, compared to 58% for the three months ended September 30, 2022. The decrease in gross margin was primarily due to an unfavorable product mix.

Operating Expense


	Three Months Ended September 30,
(in thousands)	2023		2022		$ Difference		% Difference
Operating expense:
Selling, general and administrative	$	12,829	$	11,678	$	1,151	10	%
Research, development and engineering	2,719		2,776		(57)		(2)	%
Amortization of intangible assets	929		987		(58)		(6)	%
Total operating expense	$	16,477	$	15,441	$	1,036	7	%

Our selling, general and administrative expense increased ~~$0.4~~$1.2 million, or ~~14%~~10%, to ~~$3.5 million compared to $3.1~~$12.8 million for the three months ended September 30, ~~2016. The increase in cost of Technology Development segment revenues was attributable~~2023, compared to ~~additional headcount and the increased utilization of subcontractors to support the growth in our research contracts.~~

~~The cost of revenues associated with our Products and Licensing segment~~ ~~decreased~~ ~~by $0.1 million, or 4%, to $3.6~~$11.7 million for the three months ended September 30, ~~2017 compared to~~ ~~$3.8 million~~ ~~for the three months ended September 30, 2016. This slight decrease~~2022. The increase in ~~cost of revenues resulted from lower manufacturing overhead costs associated with our optoelectronic components products.~~ ~~Our overall gross margin remained substantially unchanged at 39% for the three months ended September 30, 2017 and 2016.~~

~~Operating Expense~~

Three Months Ended September 30,
2017 2016 $ Difference % Difference
Operating expense:
Selling, general and administrative $ 3,256,074
$ 3,816,679
$ (560,605 ) (15 )%
Research, development and engineering 833,811
812,050
21,761
3 %
Total operating expense $ 4,089,885
$ 4,628,729
$ (538,844 ) (12 )%

~~Our~~ selling, general and administrative was primarily driven by an increase in costs to support our global growth.

Research, development and engineering expense decreased ~~$0.6~~$0.1 million, or ~~15%~~2%, to ~~$3.3~~$2.7 million for the three months ended September 30, ~~2017~~2023, compared to ~~$3.8~~$2.8 million for the three months ended September 30, ~~2016. The decrease in selling, general and administrative expense was primarily due~~2022.

Amortization of intangible assets decreased $0.1 million, or 6%, to ~~a $0.2 million decrease in bad debt expense and a $0.2 million decrease in sales and marketing expenses resulting from lower headcount in 2017.~~

~~Research, development and engineering expense remained substantially unchanged at $0.8~~$0.9 million for the three months ended September 30, ~~2017 and 2016.~~

~~Interest Expense~~

Interest expense was $0.1 million during each of the three months ended September 30, 2017 and 2016. During the three months ended September 30, 2017, our average outstanding balance on our term loans was $3.1 million as2023, compared to ~~$4.9~~$1.0 million for the three months ended September 30, ~~2016.~~

2022.

Income ~~Tax (Benefit)/Expense From~~from Continuing Operations Before Income Taxes

~~The~~During the three months ended September 30, 2023, we recognized income ~~tax benefit~~from continuing operations before income taxes of $0.7 million compared to income from continuing operations before income taxes of $1.3 million for the three months ended September 30, 2017 was $0.1 million, which resulted in an effective tax rate from continuing operations of (34.0%), as compared to an immaterial income tax expense, based on an effective tax rate of 13.1%, from continuing operations for the three months ended September 30, 2016. The decrease in our effective tax rate resulted from the cumulative impact of the tax benefit associated with continuing operations for the nine months ended September 30, 2017, as the intraperiod allocation of income taxes from discontinued operations resulted from the sale of the HSOR business during the three months ended September 30, 2017, and accordingly, the year-to-date value was recognized in the current period.2022.

~~Net Income/(Loss) From Continuing Operations~~Income Tax Expense

During the three months ended September 30, ~~2017,~~2023 and 2022, we recognized an income tax expense from continuing operations of $0.2 million driven by pre-tax income and a change in our estimated annual effective tax rate.

Table of Contents

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022

Revenue

Revenue for the nine months ended September 30, 2023 increased $7.1 million, or 9%, to $84.9 million compared to $77.8 million for the nine months ended September 30, 2022. The majority of the increase in revenue for the nine months ended September 30, 2023, compared to the nine months ended September 30, 2022, was due to the revenue from Luna Innovations GmbH and its wholly owned subsidiary Lios Technology, Inc. ("Lios"), which was acquired on March 10, 2022, and growth in sales of our sensing and communications test products.

Cost of Revenue and Gross Profit

Cost of revenue increased $4.8 million, or 16%, to $35.4 million for the nine months ended September 30, 2023, compared to $30.6 million for the nine months ended September 30, 2022. This increase in cost of revenue slightly outpaced our sales growth. Our overall gross margin for the nine months ended September 30, 2023 was 58%, compared to 61% for the nine months ended September 30, 2022.

Operating Expense


	Nine Months Ended September 30,
(in thousands)	2023		2022		$ Difference		% Difference
Operating expense:
Selling, general and administrative	$	39,565	$	39,733	$	(168)	—	%
Research, development and engineering	8,257		7,983		274		3	%
Amortization of intangible assets	2,839		2,794		45		2	%
Total operating expense	$	50,661	$	50,510	$	151	—	%

Selling, general and administrative expense decreased $0.2 million, to $39.6 million for the nine months ended September 30, 2023, compared to $39.7 million for the nine months ended September 30, 2022. Selling, general and administrative expense decreased primarily due to efforts to remove redundant expenses on a global basis, partially offset by an increase in costs to support our global growth and expenses from the acquired Lios operations.

Research, development and engineering expense increased $0.3 million, or 3%, to $8.3 million for the nine months ended September 30, 2023, compared to $8.0 million for the nine months ended September 30, 2022.

Amortization of intangible assets was $2.8 million for each of the nine months ended September 30, 2023 and 2022.

Loss from Continuing Operations Before Income Taxes

During the nine months ended September 30, 2023, we recognized a loss from continuing operations before income taxes of ~~$0.4~~$2.7 million compared to a loss from continuing operations before income taxes of $0.3 million for the three months ended September 30, 2016. After tax, our net income from continuing operations was $0.5 million for the three months ended September 30, 2017, compared to a net loss from continuing operations of $0.4 million for the three months ended September 30, 2016.

~~Net Income/(Loss) From Discontinued Operations~~

For the three months ended September 30, 2017, we recognized net income from discontinued operations of $15.2 million compared to a net loss from discontinued operations of $0.1 million for the three months ended September 30, 2016. For the three months ended September 30, 2017, our net income from discontinued operations included $0.1 million associated with the operations of the HSOR business prior to its sale in addition to a $15.1 million after tax gain recognized on the sale of the HSOR business. For the three months ended September 30, 2016, our net loss from discontinued operations included a $0.1 million loss associated with the operations of the HSOR business.

~~Nine Months Ended September 30, 2017 Compared to Nine Months Ended September 30, 2016~~

~~Revenues~~

Nine Months Ended September 30,
2017 2016 $ Difference % Difference
Revenues:
Technology development $ 13,428,428
$ 11,772,731
$ 1,655,697
14 %
Products and licensing 19,593,648
18,301,631
1,292,017
7 %
Total revenues $ 33,022,076
$ 30,074,362
$ 2,947,714
10 %

~~Technology Development segment revenues increased $1.7 million, or 14%, to $13.4~~$3.6 million for the nine months ended September 30, ~~2017 compared to $11.8 million for~~2022.

Income Tax Benefit

For the nine months ended September 30, ~~2016. The increase for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016 was realized primarily in our intelligent systems, nanomaterials~~2023 and ~~biomedical technologies groups.~~

~~Products~~2022 we recognized an income tax benefit from continuing operations of $0.7 million and ~~Licensing segment revenues increased $1.3~~$0.5 million, or 7%, to $19.6 million for the nine months ended September 30, 2017 compared to $18.3 million for the nine months ended September 30, 2016. The increase in Products and Licensing segment revenues was primarily driven by an increase in our sales of optical backscatter reflectometer instruments and optoelectronic components.

~~Cost of Revenues and Gross Profit~~

Nine Months Ended September 30,
2017 2016 $ Difference % Difference
Cost of revenues:
Technology development $ 10,045,261
$ 8,986,312
$ 1,058,949
12 %
Products and licensing 10,201,459
9,954,987
246,472
2 %
Total cost of revenues 20,246,720
18,941,299
1,305,421
7 %
Gross profit 12,775,356
$ 11,133,063
$ 1,642,293
15 %

Costs of Technology Development segment revenues increased $1.1 million, or 12%, to $10.0 million for the nine months ended September 30, 2017, compared to $9.0 million the nine months ended September 30, 2016. This increase was primarily driven by increases in direct labor and subcontractor costs over the same period to support the growth in research projects.

Costs of Products and Licensing segment revenues increased $0.2 million, or 2%, to $10.2 million for the nine months ended September 30, 2017 compared to $10.0 million for the nine months ended September 30, 2016. The increase in product and licensing costs is attributable to the component costs associated with increased volume of optical backscatter reflectometer instrument sales during the nine months ended September 30, 2017. Products and Licensing segment costs increased in accordance with the increase in Products and Licensing segment revenues over the same period, taking into account the gross margin effect of the product mix. Our overall gross margin for the nine months ended September 30, 2017 increased to 39% compared to 37% for the nine months ended September 30, 2016.

~~Operating Expense~~

Nine Months Ended September 30,
2017 2016 $ Difference % Difference
Operating expense:
Selling, general and administrative $ 10,345,964
$ 11,296,389
$ (950,425 ) (8 )%
Research, development and engineering 2,581,473
2,789,801
(208,328 ) (7 )%
Total operating expense $ 12,927,437
$ 14,086,190
$ (1,158,753 ) (8 )%

Selling, general and administrative expenses decreased $1.0 million, or 8%, to $10.3 million for the nine months ended September 30, 2017 compared to $11.3 million for the nine months ended September 30, 2016. The decrease in selling, general and administrative expenses year to date is primarily related to a $0.2 million decrease in bad debt expense, a $0.2 million decrease in share based compensation expense, and a $0.4 million decrease in sales and marketing costs in our Lightwave division driven by reduction in personnel and reduction in commissions related to a shift in sales to areas without distributors or salesmen.

Research, development and engineering expense decreased $0.2 million, or 7%, to $2.6 million for the nine months ended September 30, 2017 compared to $2.8 million for the nine months ended September 30, 2016 due to decreased engineering costs in internal research for our Terahertz product as more engineering time was spent on externally funded research activities and, accordingly, included in Technology Development cost of revenues.

~~Interest Expense~~

Interest expense for each of the nine months ended September 30, 2017 and 2016 was $0.2 million. During the first nine months of 2017, our average outstanding loan balance was $3.5 million as compared to $5.4 million for the nine months ended September 30, 2016.

~~Income Tax Benefit~~

respectively. The income tax benefit for the nine months ended September 30, ~~2017~~2023 was ~~$0.1 million, which resulted in an effective~~primarily due to the pre-tax loss and favorable benefit from certain discrete tax ~~rate from continuing operations of 18.8%, as compared to an~~adjustments. The income tax benefit ~~of $0.2 million, reflecting an effective tax rate of 5.4%, from continuing operations~~ for the nine months ended September 30, ~~2016. The increase in our effective tax rate for continuing operations for 2017 as compared to 2016,~~2022 was primarily due to the pre-tax loss and R&D tax credits, which was partially offset by an ~~increase in the intra-period allocation of tax~~unfavorable GILTI impact and losses for which no benefit ~~from discontinued operations.~~

can be recorded due to valuation allowances.

Net ~~Loss From Continuing Operations~~

~~During the nine months ended September 30, 2017 we incurred a loss~~(Loss)/Income from continuing operations before income taxes of $0.3 million compared to a loss from continuing operations before income taxes of $3.2 million during the nine months ended September 30, 2016. After tax, our net loss from continuing operations was $0.3 million for the nine months ended September 30, 2017, compared to a net loss from continuing operations of $3.0 million for the nine months ended September 30, 2016.

~~Net Income From~~ Discontinued Operations

For the nine months ended September 30, ~~2017,~~2023, we recognized ~~net income~~a loss from discontinued operations, net of ~~$14.5~~income taxes, of $1.0 million ~~compared~~which was due to ~~$0.3 million for~~a change in estimate related to the collection of an outstanding unbilled receivable balance previously recorded at December 31, 2022. For the nine months ended September 30, ~~2016. Net~~2022, we recognized income from discontinued operations, ~~for the nine months ended September 30, 2017 included an after tax~~net of income taxes, of $11.5 million, which primarily consisted of a gain of ~~$15.1~~$10.9 million, ~~recognized~~net of tax, on the sale of the HSOR business offset by an after tax loss of $0.6 million associated with the operations of the HSOR business prior to its sale. Net income from discontinued operations for the nine months ended September 30, 2016 included the after tax income of $0.3 million associated with the operations of HSOR during the period.Luna Labs.

Table of Contents

Liquidity and Capital Resources

At September 30, ~~2017,~~2023, our total cash and cash equivalents were ~~$38.5~~$6.0 million. We require cash to: (i) fund our operating expenses, working capital requirements, and outlays for strategic acquisitions and investments; (ii) service our debt, including principal and interest; (iii) conduct research and development; (iv) incur capital expenditures; and (v) repurchase our common stock. As part of our business strategy, we review acquisition and divestiture opportunities on a regular basis.

We ~~currently have a Loan~~believe that the key factors that could affect our internal and ~~Security Agreement~~external sources of cash include:

•Changes in demand for our products, competitive pricing pressures, supply chain constraints, effective management of our manufacturing capacity, our ability to achieve further reductions in operating expenses, our ability to make progress on the achievement of our business strategy goals, and our ability to make the research and development expenditures required to remain competitive in our business.

•Our access to bank financing and the debt and equity capital markets that could impair our ability to obtain needed financing on acceptable terms or to respond to business opportunities and developments as they arise, including interest rate fluctuations, macroeconomic conditions, sudden reductions in the general availability of lending from banks or the related increase in cost to obtain bank financing and our ability to maintain compliance with ~~Silicon Valley Bank ("SVB")~~covenants under ~~which we have two term loans with an aggregate original borrowing amount of $7.0 million.~~ our debt agreements in effect from time to time.

As of September 30, ~~2017, these term loans~~2023, we had ~~an aggregate~~outstanding borrowings under our Term Loan and Revolving Line of $17.2 million and $14.7 million, respectively. We may repay and reborrow advances under the Revolving Line from time to time pursuant to the Revolving Line of Credit Note. The unused Revolving Line totaled $0.3 million at September 30, 2023.

The Term Loan matures on June 21, 2027. The Term Loan amortizes at a rate equal to 10% for the first year, 15% for years two and three, 20% in year four and 15% in year five, in each case payable on a quarterly basis. The remaining balance is due on maturity. Accrued interest is due and payable on the first day of each month and the outstanding principal balance and any accrued but unpaid interest will be due and payable on June 21, 2027. The Term Loan bears interest at a floating per annum rate equal to the sum of ~~$2.9 million. One term loan, with a balance~~(a) the daily simple secured overnight financing rate, or Daily Simple SOFR, plus (b) an SOFR adjustment of ~~$.4 million as of September 30, 2017, matures~~ten basis points (0.10%), plus (c) an applicable margin. The applicable margin ranges from 1.75% to 2.75% per annum, depending on ~~December 1, 2018.~~ the Net Leverage Ratio (as defined in the Loan Agreement). We may prepay the Term Loan without penalty or premium.

The ~~other term loan, with a balance of $2.5 million as of September 30, 2017, matures~~Revolving Line expires on ~~May 1, 2019. The term loans~~June 21, 2027. Borrowings under the Revolving Line bear interest at a floating ~~prime~~per annum rate equal to the sum of (a) Daily Simple SOFR, plus ~~2%. We may prepay amounts~~(b) a SOFR adjustment of ten basis points (0.10%), plus (c) an applicable margin. The applicable margin ranges from 1.75% to 2.75% per annum, depending on the Net Leverage Ratio. Accrued interest is due ~~under~~and payable on the ~~term loans at~~first day of each month and the outstanding principal balance and any ~~time, subject to prepayment penalties of up to 2%~~accrued but unpaid interest is due and payable on June 21, 2027. The unused portion of the ~~amount of prepayment. Amounts due under~~Revolving Line accrues a fee equal to 0.20% per annum multiplied by the ~~term loans are secured by substantially all~~quarterly average unused amount.

Additional details of our assets, including intellectual property, personal property and bank accounts. The term loans contain customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated debt documents, incorrectness of representations and warrantiesLoan Agreement can be found in

any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs, SVB may declare due immediately all borrowings under the credit facility and foreclose on the collateral. Furthermore, an event of default under the credit facility would result in an increase Note 7, "Debt" in the ~~interest rate on any amounts outstanding. As of September 30, 2017, we were~~notes to our unaudited condensed consolidated financial statements included elsewhere in ~~compliance with all covenants under the Loan and Security Agreement.~~

this Form 10-Q.

We believe that our cash ~~balance~~and cash equivalents and availability under our revolver as of September 30, ~~2017~~2023 will provide adequate liquidity for us to meet our working capital needs over the next twelve ~~months.~~months from the date of issuance of the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Additionally, we believe that should we have the need for increased capital spending to support our planned growth, we will be able to fund such growth through either third-party financing on competitive market terms or through our available cash. However, these estimates are based on assumptions that may prove to be incorrect, including as a result of changes in the macroeconomic environment and their potential impact to our business. If we require additional capital beyond our current balances of cash and cash equivalents, this additional capital may not be available when needed, on reasonable terms, or at all. Moreover, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide.

Table of Contents

Discussion of Cash Flows

~~Recent Activity~~

Nine Months Ended September 30,
2017 2016 $ Difference
Net cash provided by/(used in) operating activities $ 581,386
$ (785,878 ) $ 1,367,264
Net cash provided by/(used in) investing activities 26,743,345
(1,750,547 ) 28,493,892
Net cash used in financing activities (1,612,752 ) (1,744,464 ) 131,712
Net increase/(decrease) in cash and cash equivalents $ 25,711,979
$ (4,280,889 ) $ 29,992,868


	Nine Months Ended September 30,
(in thousands)	2023		2022
Net cash used in operating activities	$	(8,140)	$	(3,285)
Net cash used in investing activities	(1,845)		(11,396)
Net cash provided by financing activities	9,995		7,226
Effect of exchange rate changes on cash and cash equivalents	(6)		(1,784)
Net increase/(decrease) in cash and cash equivalents	$	4	$	(9,239)

During the first nine months of 2017, operations provided $0.6 million of cash, as compared to the same period in 2016 in which operations used $0.8 million of cash. During the first nine months of 2017, net cash provided by operating activities consisted of our net income of $14.2 million, which included a gain on the sale of our HSOR business, net of income tax, of $15.1 million, non-cash charges for depreciation and amortization of $2.2 million and share-based compensation of $0.5 million, and a net cash outflow of $1.3 million from changes in working capital (principally driven by a decrease in accounts payable and accrued expenses of $1.6 million and an increase in inventory of $2.3 million, partially offset by a reduction in accounts receivable of $2.1 million).

During the first nine months of 2016, the $0.8 million of cash used in operating activities consisted of our net loss of $2.7 million which included charges for depreciation and amortization of $2.8 million and share-based compensation of $0.7 million. Additionally, changes in working capital resulted in a net cash outflow of $1.8 million, principally driven by a reduction in accounts payable and accrued liabilities of $1.1 million, a decrease in inventory of $1.0 million, an increase in other current assets of $0.4 million, and an increase of $1.2 million in accounts receivable.

~~Our cash from investing activities for~~ the nine months ended September 30, ~~2017~~2023, net cash used in operating activities was $8.1 million compared to $3.3 million for the comparable period of 2022. Overall, this net increase in use of operating cash was driven by an increase in working capital, including higher inventory levels to support our sales growth and ~~2016 included purchases~~to mitigate longer order lead times because of ~~equipment, capitalized costs associated with the prosecution of patents as well as proceeds from the sale of our HSOR business in August 2017. Cash provided by investing activities for~~global supply chain issues.

During the nine months ended September 30, ~~2017 included~~2023, cash used in investing activities was $1.8 million which decreased by $9.6 million from 2022. The decrease in net cash used in investing activities was primarily due to acquisition related activity during the prior year. The cash outflow for the acquisition of Lios in the 2022 period totaled $22.1 million, and was partially offset from the proceeds from the sale of ~~our HSOR business of $28.0 million, partially offset by $0.9 million of fixed asset additions~~discontinued operations totaling $13.0 million. Excluding acquisitions and ~~$0.4 million of capitalized intellectual property costs. Cash~~sales transactions, cash used in investing ~~activities~~decreased by $0.4 million primarily due to reduced capital expenditures for normal business needs.

During the nine months ended September 30, ~~2016 included fixed asset additions~~2023, cash provided by financing activities was $10.0 million, compared to $7.2 million for the comparable period in 2022. Cash provided during the 2023 period consisted primarily of ~~$1.4~~net proceeds of $8.7 million ~~and capitalized intellectual property costs of $0.3 million.~~

~~Net cash~~from new borrowings used into support operating activities. Cash provided by financing activities during the ~~nine months ended September 30, 2017 and 2016 included~~2022 period consisted primarily of net borrowings used to partially fund the ~~repayment~~acquisition of the long term debt and repayments of capital lease obligations. In the aggregate, these activities resulted in net cash outflows of $1.6 million and $1.7 million for the nine months of 2017 and 2016, respectively.Lios.

~~Off-Balance Sheet Arrangements~~

~~We have no material off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4)(ii).~~



ITEM 3.			QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. We do not hold or issue financial instruments for trading purposes or have any derivative financial instruments. Our exposure to market risk is limited to interest rate fluctuations, due to changes in the general level of U.S. interest rates, and foreign currency exchange rates.

Interest Rate Risk

We do not use derivative financial instruments as a hedge against interest rate fluctuations, and, as a result, ~~interest income earned on our cash and cash equivalents and short-term investments is~~we are subject to changes in interest rates. However, we believe that the impact of these fluctuations does not have a material effect on our financial position due to the immediately available liquidity or short-term nature of these financial instruments.

~~We are exposed~~ to interest rate ~~fluctuations~~risk on our Term Loan and Revolving Line with interest rates at a floating per annum rate equal to the sum of (a) Daily Simple SOFR, plus (b) a SOFR adjustment of ten basis points (0.10%), plus (c) an applicable margin. The applicable margin ranges from 1.75% to 2.75% per annum, depending on the Net Leverage Ratio as ~~a result of our term loans with SVB having a variable interest rate. We do not currently use derivative instruments to alter~~defined in the ~~interest rate characteristics of our debt. For~~credit agreement governing the ~~principal amount of $2.9 million outstanding under the term loans as~~Term Loan and Revolving Line. As of September 30, ~~2017,~~2023, we had outstanding borrowings under our Term Loan and Revolving Line of $17.2 million and $14.7 million, respectively, at the weighted-average variable interest rate of 7.90%. At this borrowing level, a ~~change~~0.25% increase in interest rates would have had an unfavorable annual impact on our pre-tax earnings and cash flows in the ~~interest rate by one percentage point for one year would result in a change in our annual interest expense~~amount of ~~$29,167.~~

Although we believe that this measure is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in our credit quality, composition of our balance sheet and other business developments that could affect our interest rate exposure. Accordingly, no assurances can be given that actual results would not differ materially from the potential outcome simulated by this estimate.approximately $80 thousand.

Foreign Currency Exchange Rate Risk

~~As of September 30, 2017, all payments made under~~Our foreign currency exposure is primarily related to our ~~research contracts have been denominated in U.S. dollars. Our product sales to foreign customers are also generally denominated in U.S. dollars, and we generally do not receive payments~~net investment in foreign ~~currency. As such, we are not directly exposed to significant currency~~subsidiaries. Foreign exchange rate gains or losses resulting from ~~fluctuations in~~the translation of our foreign ~~exchange rates.~~

operations into U.S. dollars are reflected as a cumulative translation adjustment and do not affect our results of operations.

Table of Contents



ITEM 4.			CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.

Under the supervision and with the participation of our management, including our ~~principal executive officer~~President and Chief Executive Officer and our ~~principal financial officer,~~Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this ~~Quarterly Report.~~quarterly report. Based on this evaluation, our ~~principal executive officer~~President and Chief Executive Officer and our ~~principal financial officer~~Chief Financial Officer have concluded that, as of September 30, ~~2017,~~2023, our disclosure controls and procedures were ~~effective at the reasonable assurance level.~~

effective.

Changes in Internal Control over Financial Reporting

~~No change~~There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended September 30, ~~2017~~2023 that ~~has~~ materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION



ITEM 1.			LEGAL PROCEEDINGS

~~In June 2015,~~From time to time, we ~~received a letter~~may become involved in litigation or claims arising out of ~~final determination from~~our operations in the ~~Defense Contract~~normal course of business. Management ~~Agency ("DCMA") regarding~~currently believes the ~~allowability~~amount of certain costs we included in our billings under cost-plus type research contracts during 2007. In conjunction with the DCMA's determination of those costs as expressly unallowable under the provisions of the Federal Acquisition Regulations, the DCMA assessed penalties and interest to us totaling $1.1 million. In July 2015, we filed an appeal of the assessed penalties and interest with the Armed Services Board of Contract Appeals ("ASBCA"). A hearing was heldultimate liability, if any, with respect to ~~this appeal in January 2017, and a decision has~~these actions will not ~~yet been reached by ASBCA. In April 2017, we made a settlement offer of $150,000 to DCMA, and we have accrued that amount in~~materially affect our financial ~~statements as~~position, results of ~~September 30, 2017. In May 2017, the DCMA declined our settlement offer. The appeals process remains ongoing.~~operations, or liquidity.

~~For additional information regarding our legal proceedings, please refer to our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017.~~



ITEM 1A.			RISK FACTORS

You should carefully consider the risks described below before deciding whether to invest in our common stock. The risks described below are not the only ones we face. Additional risks not presently known to us or that we currently believe are immaterial may also impair our business operations and financial results. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected. In such case, the trading price of our common stock could decline and you could lose all or part of your investment. Our filings with the SEC also contain forward-looking statements that involve risks or uncertainties. Our actual results could differ materially from those anticipated or contemplated by these forward-looking statements as a result of a number of factors, including the risks we face described below, as well as other variables that could affect our operating results. Past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

~~RISKS RELATING TO OUR BUSINESS GENERALLY~~RISK FACTORS SUMMARY

Our ~~technology~~business is subject to a ~~license~~number of risks and uncertainties, including those risks discussed at-length below. These risks include, among others, the following:

•Risks Relating to our Business

◦We depend on third-party vendors for specialized components in our manufacturing operations, making us vulnerable to supply shortages and price fluctuations that could harm our business.

◦As a provider of contract research to the U.S. government, we are subject to federal rules, regulations, audits and investigations, the violation or failure of which could adversely affect our business.

◦Some of our technology is in-licensed from Intuitive Surgical, Inc., which is revocable in certain circumstances. Without this license, we cannot continue to market, manufacture or sell a portion of our fiber-optic products.

As◦Our products must meet exacting specifications, and defects and failures may occur, which may cause customers to return or stop buying our products.

◦The markets for many of our products are characterized by changing technology which could cause obsolescence of our products, and we may incur substantial costs in delivering new products.

•Risks Relating to our Operations and Business Strategy

◦If we fail to properly evaluate and execute our strategic initiatives, it could have an adverse effect on our future results and the market price of our common stock.

◦We are experiencing impacts from inflationary pressures, including with respect to labor and materials costs, which could adversely impact our profitability and cash flow.

◦Health epidemics, including the COVID-19 pandemic, have had, and could in the future have, an adverse impact on our business, operations, and the markets and communities in which we and our customers and suppliers operate.

•Risks Relating to our Regulatory Environment

◦Our operations are subject to domestic and foreign laws, regulations and restrictions, and noncompliance with these laws, regulations and restrictions could expose us to fines, penalties, suspension or debarment, which could have a material adverse effect on our profitability and overall financial position.

◦We are or may become subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.

•Risks Relating to our Intellectual Property

◦Our proprietary rights may not adequately protect our technologies.

◦Third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.

•Risks Relating to our Common Stock

Table of Contents

◦Our common stock price has been volatile and we expect that the price of our common stock will fluctuate substantially in the future, which could cause you to lose all or a substantial part of ~~the sale~~your investment.

◦Anti-takeover provisions in our amended and restated certificate of ~~certain assets to Intuitive Surgical, Inc. ("Intuitive")~~incorporation and bylaws and Delaware law could discourage or prevent a change in 2014, we entered into a license agreement with Intuitive pursuant to which we received rights to use all of our transferred technology outside the field of medicine and in respect of our existing non-shape sensing products in certain non-robotic medical fields. This license back to us is revocablecontrol, even if after notice and certain time periods, we were to (i) challenge the validity or enforceability of the transferred patents and patent applications, (ii) commercialize our fiber optical shape sensing and localization technology in the field of medicine (except to perform on a development and supply project for Hansen Medical, Inc.), (iii) violate our obligations relatedan acquisition would be beneficial to our ~~ability~~stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to ~~sublicense in the field of medicine~~replace or ~~(iv) violate~~remove our confidentiality obligations in a manner that advantages a competitor in the field of medicine and not cure such violation. Maintaining this license is necessary for us to conduct our fiber-optic products business, both for our telecom products and our ODiSI sensing products. If this license were to be revoked by Intuitive, we would no longer be able to market, manufacture or sell these products which would severely limit our ability to continue operations.current management.

RISKS RELATING TO OUR BUSINESS

We depend on third-party vendors for specialized components in our manufacturing operations, making us vulnerable to supply shortages and price fluctuations that could harm our business.

We primarily rely on third-party vendors for the manufacture of the specialized components used in our products. The highly specialized nature of our supply requirements poses risks that we may not be able to locate additional sources of the specialized components required in our business. For example, there are few manufacturers who produce the special lasers used in our optical test equipment. Our reliance on these vendors subjects us to a number of risks that could negatively affect our

ability to manufacture our products and harm our business, including interruption of supply. Although we are now manufacturing tunable lasers in low-rate initial production, we expect our overall reliance on third-party vendors to continue. Any significant delay or interruption in the supply of components, or our inability to obtain substitute components or materials from alternate sources at acceptable prices and in a timely manner could impair our ability to meet the demand of our customers and could harm our business.

We depend upon outside contract manufacturers for a portion of the manufacturing process for some of our products. Our operations and revenue related to these products could be adversely affected if we encounter problems with these contract manufacturers.

Many of our products are manufactured internally. However, we also rely upon contract manufacturers to produce the finished portion of ~~some of our optoelectronic components~~certain products and ~~certain~~ lasers. Our reliance on contract manufacturers for these products makes us vulnerable to possible capacity constraints and reduced control over delivery schedules, manufacturing yields, manufacturing quality control and costs. If the contract manufacturer for our products were unable or unwilling to manufacture our products in required volumes and at high quality levels or to continue our existing supply arrangement, we would have to identify, qualify and select an acceptable alternative contract manufacturer or move these manufacturing operations to internal manufacturing facilities. An alternative contract manufacturer may not be available to us when needed or may not be in a position to satisfy our quality or production requirements on commercially reasonable terms, including price. Any significant interruption in manufacturing our products would require us to reduce the supply of products to our customers, which in turn would reduce our revenue, harm our relationships with the customers of these products and cause us to forego potential revenue opportunities.

As a ~~provider of contract research to the~~ U.S. government contractor, we are subject to federal rules, regulations, audits and investigations, the violation or failure of which could adversely affect our business.

We must comply with and are affected by laws and regulations relating to the award, administration and performance of U.S. government contracts. Government contract laws and regulations affect how we do business with our government customers and, in some instances, impose added costs on our business. A violation of a specific law or regulation could result in the imposition of fines and penalties, termination of our contracts or debarment from bidding on future contracts. In some instances, these laws and regulations impose terms or rights that are more favorable to the government than those typically available to commercial parties in negotiated transactions. ~~For example,~~Such terms or rights many allow government customers, among others, to:

•terminate existing contracts for convenience with short notice;

•reduce orders or otherwise modify contracts;

•for contracts subject to the ~~U.S. government may~~Truth in Negotiations Act, reduce the contract price or cost where it was increased because a contractor or subcontractor furnished cost or pricing data during negotiations that was not complete, accurate, and current;

•for some contracts, (i) demand a refund, make a forward price adjustment, or terminate ~~any~~a contract for default if a contractor provided inaccurate or incomplete data during the contract negotiation process, and (ii) reduce the contract price under triggering circumstances, including the revision of ~~our government~~price lists or other documents upon which the contract award was predicated;

Table of Contents

•cancel multi-year contracts and related orders if funds for contract performance for any subsequent year become unavailable;

•decline to exercise an option to renew a multi-year contract or issue task orders in ~~general, subcontracts, at~~connection with indefinite delivery/indefinite quantity contracts;

•claim rights in solutions, systems, or technology produced by us, appropriate such work-product for their ~~convenience, as well as~~continued use without continuing to contract for ~~default~~our services, and disclose such work-product to third parties, including other government agencies and our competitors, which could harm our competitive position;

•prohibit future procurement awards with a particular agency due to a finding of organizational conflicts of interest based ~~on performance.~~upon prior related work performed for the agency that would give a contractor an unfair advantage over competing contractors, or the existence of conflicting roles that might bias a contractor’s judgment; and

•subject the award of contracts to protest by competitors, which may require the contracting federal agency or department to suspend our performance pending the outcome of the protest and may also result in a requirement to resubmit offers for the contract or in the termination, reduction, or modification of the awarded contract; and suspend or debar us from doing business with the applicable government.

In addition, U.S. government agencies, including the Defense Contract Audit Agency and the Department of Labor, routinely audit and investigate government contractors. These agencies review a contractor’s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards. The U.S. government also may review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded. If an audit uncovers the inclusion of certain claimed costs deemed to be expressly unallowable, or improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. government. In addition, our reputation could suffer serious harm if allegations of impropriety were made against us. In June 2015, we received a determination from the Defense Contract Management Agency ("DCMA") of expressly unallowable costs included in our claimed costs for the 2007 contract year. As a result of that determination, the DCMA assessed us penalties, interest and over billings of $1.1 million. We have appealed that assessment, and our appeal is currently pending. In April 2017, we also made a settlement offer of $150,000 to the DCMA, which the DCMA subsequently declined. Depending on the outcome of this appeal and the response to our settlement offer, we could be required to make payments that have a material adverse effect on our financial position.

In addition to the risk of government audits and investigations, U.S. government contracts and grants impose requirements on contractors and grantees relating to ethics and business practices, which carry civil and criminal penalties including monetary fines, assessments, loss of the ability to do business with the U.S. government and certain other criminal penalties.

We may also be prohibited from using certain foreign-sourced parts, components, materials, or other items in the performance of our government contracts or from commercially selling certain products that we develop ~~under our Technology Development segment or related products based on the same core technologies~~ if the U.S. government determines that the commercial availability of those products could pose a risk to national security. ~~For example, certain~~

Some of our ~~wireless technologies have been classified as secret by the U.S. government and as a result~~technology is in-licensed from Intuitive Surgical, Inc., which is revocable in certain circumstances. Without this license, we cannot continue to market, manufacture or sell ~~them commercially. Any~~a portion of ~~these determinations would limit~~our fiber-optic products.

As a part of the sale of certain assets to Intuitive Surgical, Inc. ("Intuitive") in 2014, we entered into a license agreement with Intuitive pursuant to which we received rights to use all of our transferred technology outside the field of medicine and in respect of our existing non-shape sensing products in certain non-robotic medical fields. This license back to us generally covers our Phoenix laser, OVA, OBR and ODiSI products. This license is revocable if after notice and certain time periods, we were to (i) challenge the validity or enforceability of the transferred patents and patent applications, (ii) commercialize our fiber optical shape sensing and localization technology in the field of medicine, (iii) violate our obligations related to our ability to ~~generate product sales and license revenues.~~

We rely and will continue to rely on contracts and grants awarded under the SBIR program for a significant portion of our revenues. A finding by the SBA that we no longer qualify to receive SBIR awards could adversely affect our business.

We compete as a small business for some of our government contracts. Our revenues derived from the SBIR program account for a significant portion of our consolidated total revenues, and contract research, including SBIR contracts, will remain a significant portion of our consolidated total revenues for the foreseeable future. For the nine months ended September 30, 2017 and 2016, revenues generated under the SBIR program represented 32% and 35%, respectively, of our total revenues.

~~We may not continue to qualify to participate~~sublicense in the ~~SBIR program~~field of medicine or to receive new SBIR awards from federal agencies. In order to qualify for SBIR contracts and grants, we must meet certain size and ownership eligibility criteria. These eligibility criteria are applied as of the time of the award of(iv) violate our confidentiality obligations in a ~~contract or grant. A company can be declared ineligible for a contract award as a result of a size challenge filed with the SBA by~~manner that advantages a competitor ~~or a federal agency.~~

~~In order~~in the field of medicine and not cure such violation. Maintaining this license is necessary for us to be eligible for SBIR contracts and grants, under current SBA rules we must be more than 50% owned and controlled by individuals who are U.S. citizens or permanent resident aliens, and/or other small business concerns (each of which is more than 50% owned and controlled by individuals who are U.S. citizens or permanent resident aliens) or certain qualified investment companies. In the event our institutional ownership significantly increases, either because of increased buying by institutions or selling by individuals, we could lose eligibility for new SBIR contracts and grants.

Also, in order to be eligible for SBIR contracts and grants, the number of our employees, including those of any entities that are considered to be affiliated with us, cannot exceed 500. As of September 30, 2017, we had approximately 190 full-time employees. In determining whether we are affiliated with any other entity, the SBA may analyze whether another entity controls or has the power to control us. Carilion Clinic is our largest institutional stockholder. Since early 2011, a formal size determination by the SBA that focused on whether or not Carilion is or was our affiliate has been outstanding. Although we do not believe that Carilion has or had the power to control our company, we cannot assure you that the SBA will interpret its regulations in our favor on this question. If the SBA were to make a determination that we are or were affiliated with Carilion, we would exceed the size limitations, as Carilion has over 500 employees. In that case, we would lose eligibility for new SBIR contracts and grants and other awards that are set aside for small businesses based on the criterion of number of employees, and the relevant government agency would have the discretion to suspend performance on existing SBIR grants. The loss of our eligibility to receive SBIR awards would have a material adverse impact on our revenues, cash flows and our ability to fund our growth.

~~Moreover, as~~conduct our business ~~grows, it is foreseeable that we will eventually exceed~~related to the ~~SBIR size limitations, in which case we may be required to seek alternative sources of revenues or capital.~~

A decline in government research contract awards or government funding for existing or future government research contracts, including SBIR contracts, could adversely affect our revenues, cash flows and ability to fund our growth.

Technology Development segment revenues, which consist primarily of government-funded research, accounted for 41% and 39% of our consolidated total revenues for the nine months ended September 30, 2017 and 2016, respectively. As a result, we are vulnerable to adverse changes in our revenues and cash flows if a significant number of our research contracts and subcontractsaforementioned products. If this license were to be simultaneously delayed or canceled for budgetary, performance or other reasons. For example, the U.S. government may cancel these contracts at any time without cause and without penalty or may change its requirements, programs or contract budget, any of which could reduce our revenues and cash flows from U.S. government research contracts. Our revenues and cash flows from U.S. government research contracts and subcontracts could also be reducedrevoked by ~~declines or other changes in U.S. defense, homeland security and other federal agency budgets. In addition,~~Intuitive, we compete as a small business for some of these contracts, and in order to maintain our eligibility to compete as a small business, we, together with any affiliates, must continue to meet size and revenue limitations established by the U.S. government.

Our contract research customer base includes government agencies, corporations and academic institutions. Our customers are not obligated to extend their agreements with us and may elect not to do so. Also, our customers’ priorities regarding funding for certain projects may change and funding resources maywould no longer be ~~available at previous levels.~~

~~In addition, the Budget Control Act commits the U.S. government~~able to reduce the federal deficit by $1.2 trillion over ten years through a combination of automatic, across-the-board spending cuts and caps on discretionary spending. This “sequestration” under the Budget Control Act,market, manufacture or sell these products, which ~~is split equally between defense and non-defense programs, went into effect on March 1, 2013. Any spending cuts required by “sequestration”~~ could have a material adverse effect on our ~~Technology Development revenues and, consequently, our results of~~ operations. ~~While the exact manner in which this~~

“sequestration” may impact our business remains unclear, funding for programs in which we participate could be reduced, delayed or canceled. Our ability to obtain new contract awards also could be negatively affected.

In addition to contract cancellations and changes in agency budgets, our future financial results may be adversely affected by curtailment of or restrictions on the U.S. government’s use of contract research providers, including curtailment due to government budget reductions and related fiscal matters or any legislation or resolution limiting the number or amount of awards we may receive. These or other factors could cause U.S. defense and other federal agencies to conduct research internally rather than through commercial research organizations or direct awards to other organizations, to reduce their overall contract research requirements or to exercise their rights to terminate contracts. Alternatively, the U.S. government may discontinue the SBIR program or its funding altogether. Also, SBIR regulations permit increased competition for SBIR awards from companies that may not have previously been eligible, such as those backed by venture capital operating companies, hedge funds and private equity firms. Any of these developments could limit our ability to obtain new contract awards and adversely affect our revenues, cash flows and ability to fund our growth.

~~Our narrowed scope and focus may make it more difficult for us to achieve or maintain operating profitability~~

Through the recent sale of our HSOR business to a third party, we have reduced our overall size and narrowed our focus. Although we anticipate realizing cost savings as a result of the sale of the HSOR operations, we will continue to incur significant operating expenses associated with our public company infrastructure. Accordingly, we will need to significantly increase the revenue we generate from our remaining operations in order to achieve or maintain operating profitability. While we intend to use a portion of the proceeds from the sale of the HSOR business to invest in our fiber optic sensing business, there can be no guarantee that these efforts will result in increased revenues sufficient to achieve or maintain profitability.

Our failure to attract, train and retain skilled employees or members of our senior management and to obtain necessary security clearances for such persons or maintain a facility security clearance would adversely affect our business and operating results.

The availability of highly trained and skilled technical and professional personnel is critical to our future growth and profitability. Competition for scientists, engineers, technicians and professional personnel is intense and our competitors aggressively recruit key employees. In the past, we have experienced difficulties in recruiting and hiring these personnel as a

Table of Contents

result of the tight labor market in certain fields. Any difficulty in hiring or retaining qualified employees, combined with our growth strategy and future needs for additional experienced personnel, particularly in highly specialized areas such as nanomaterial manufacturing and fiber optic sensing technologies, may make it more difficult to meet all of our needs for these employees in a timely manner. Although we intend to continue to devote significant resources to recruit, train and retain qualified employees, we may not be able to attract and retain these employees, especially in technical fields in which the supply of experienced qualified candidates is limited, or at the senior management level. Any failure to do so would have an adverse effect on our business. Any loss of key personnel could have a material adverse effect on our ability to meet key operational objectives, such as timely and effective project milestones and product introductions, which in turn could adversely affect our business, results of operations and financial condition.

We provide certain services to the U.S. government that require us to maintain a facility security clearance and for certain of our employees and ~~our~~ board ~~chairman~~members to hold security clearances. In general, ~~the~~our failure for ~~necessary persons~~ to obtain or retain sufficient security clearances, ~~any loss by us of a facility security clearance~~ or any public reprimand related to security matters could result in a U.S. government customer terminating an existing contract, or choosing not to renew a contract or prevent us from bidding on or winning certain new government contracts.

In addition, our future success depends in a large part upon the continued service of key members of our senior management team. We do not maintain any key-person life insurance policies on our officers. The loss of any members of our management team or other key personnel could seriously harm our business.

Our business is subject to the cyclical nature of the markets in which we compete and any future downturn may reduce demand for our products and revenue.

Many factors beyond our control affect our business, including consumer confidence in the economy, interest rates, inflation, fuel prices, health crises, such as the COVID-19 pandemic, international conflicts, such as the current hostilities between Russia and Ukraine and the Israel-Hamas war, and the general availability of credit. The overall economic climate and changes in Gross National Product growth have a direct impact on some of our customers and the demand for our products. We cannot be sure that our business will not be adversely affected as a result of an industry or general economic downturn.

Our customers may reduce capital expenditures and have difficulty satisfying liquidity needs because of continued turbulence in the U.S. and global economies, resulting in reduced sales of our products and harm to our financial condition and results of operations.

In particular, our historical results of operations have been subject to substantial fluctuations, and we may experience substantial period-to-period fluctuations in future results of operations. Any future downturn in the markets in which we compete, could significantly reduce the demand for our products and therefore may result in a significant reduction in revenue or increase the volatility of the price of our common stock. Our revenue and results of operations may be adversely affected in the future due to changes in demand from customers or cyclical changes in the markets utilizing our products.

In addition, the telecommunications industry has, from time to time, experienced, and may again experience, a pronounced downturn. To respond to a downturn, many service providers may slow their capital expenditures, cancel or delay new developments, reduce their workforces and inventories and take a cautious approach to acquiring new equipment and technologies from original equipment manufacturers, which would have a negative impact on our business. Weakness in the global economy or a future downturn in the telecommunications industry may cause our results of operations to fluctuate from quarter-to-quarter and year-to-year, harm our business, and may increase the volatility of the price of our common stock.

Customer acceptance of our products is dependent on our ability to meet changing requirements, and any decrease in acceptance could adversely affect our revenue.

Customer acceptance of our products is significantly dependent on our ability to offer products that meet the changing requirements of our customers, including telecommunication, military, medical and industrial corporations, as well as government agencies. Any decrease in the level of customer acceptance of our products could harm our business.

Our products must meet exacting specifications, and defects and failures may occur, which may cause customers to return or stop buying our products.

Our customers generally establish demanding specifications for quality, performance and reliability that our products must meet. However, our products are highly complex and may contain defects and failures when they are first introduced or as new versions are released. Our products are also subject to rough environments as they are integrated into our customer products for use by the end customers. If defects and failures occur in our products, we could experience lost revenue, increased costs, including warranty expense and costs associated with customer support, delays in or cancellations or rescheduling of

Table of Contents

orders or shipments, product returns or discounts, diversion of management resources or damage to our reputation and brand equity, and in some cases consequential damages, any of which would harm our operating results. In addition, delays in our ability to fill product orders as a result of quality control issues may negatively impact our relationship with our customers. We cannot assure you that we will have sufficient resources, including any available insurance, to satisfy any asserted claims.

~~Rapidly changing standards and regulations could make our products obsolete, which would cause our revenue and results of operations to suffer.~~

We design products to conform to our customers’ requirements and our customers’ systems may be subject to regulations established by governments or industry standards bodies worldwide. Because some of our products are designed to conform to current specific industry standards, if competing or new standards emerge that are preferred by our customers, we would have to make significant expenditures to develop new products. If our customers adopt new or competing industry standards with which our products are not compatible, or the industry groups adopt standards or governments issue regulations with which our products are not compatible, our existing products would become less desirable to our customers and our revenue and results of operations would suffer.

The markets for many of our products are characterized by changing technology which could cause obsolescence of our products, and we may incur substantial costs in delivering new products.

The markets for many of our products are characterized by changing technology, new product introductions and product enhancements, and evolving industry standards. The introduction or enhancement of products embodying new technology or the emergence of new industry standards could render existing products obsolete, and result in a write down to the value of our inventory, or result in shortened product life cycles. Accordingly, our ability to compete is in part dependent on our ability to continually offer enhanced and improved products.

The success of our new product offerings will depend upon several factors, including our ability to:

•accurately anticipate customer needs;

•innovate and develop new technologies and applications;

•successfully commercialize new technologies in a timely manner;

•price products competitively and manufacture and deliver products in sufficient volumes and on time; and

•differentiate our product offerings from those of our competitors.

Some of our products are used by our customers to develop, test and manufacture their products. We therefore must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. In developing any new product, we may be required to make a substantial investment before we can determine the commercial viability of the new product. If we fail to accurately foresee our customers’ needs and future activities, we may invest heavily in research and development of products that do not lead to significant revenues.

Our inability to find new customers or retain existing customers could harm our business.

Our business is reliant on our ability to find new customers and retain existing customers. In particular, customers normally purchase certain of our products and incorporate them into products that they, in turn, sell in their own markets on an ongoing basis. As a result, the historical sales orof these products have been dependent upon the success of our customers’ products and ~~the~~our future performance ~~of our business~~ is dependent upon our success in finding new customers and receiving new orders from existing customers.

In several markets, the quality and reliability of our products are a major concern for our customers, not only upon the initial manufacture of the product, but for the life of the product. Many of our products are used in remote locations for higher value assembly, making servicing of our products unfeasible. Any failure of the quality or reliability of our products could harm our business.

~~If our customers do not qualify our products or if their customers do not qualify their products, our results of operations may suffer.~~

Most of our customers do not purchase our optoelectronics products prior to qualification of the products and satisfactory completion of factory audits and vendor evaluation. Our existing products, as well as each new product, must pass through varying levels of qualification with our customers. In addition, because of the rapid technological changes in some markets, a customer may cancel or modify a design project before we begin large-scale manufacturing and receiving revenues from the customer. It is unlikely that we would be able to recover the expenses for cancelled or unutilized custom design projects. It is difficult to predict with any certainty whether our customers will delay or terminate product qualification or the frequency with which customers will cancel or modify their projects. Any such delay, cancellation or modification could have a negative effect on our results of operations.

In addition, once a customer qualifies a particular supplier’s product or component, these potential customers design the product into their system, which is known as a design-in win. Suppliers whose products or components are not designed in are unlikely to make sales to that customer until at least the adoption of a future redesigned system. Even then, many customers may be reluctant to incorporate entirely new products into their new systems, as doing so could involve significant additional redesign efforts and increased costs. If we fail to achieve design-in wins in potential customers’ qualification processes, we will likely lose the opportunity for significant sales to those customers for a lengthy period of time.

If the end user customers that purchase systems from our customers fail to qualify or delay qualifications of any products sold by our customers that contain our products, our business could be harmed. The qualification and field testing of our customers’ systems by end user customers is long and unpredictable. This process is not under our control or that of our customers and, as a result, the timing of our sales may be unpredictable. Any unanticipated delay in qualification of one of our customers’ products could result in the delay or cancellation of orders from our customers for products included in their equipment, which could harm our results of operations.

Customer demand for our products is difficult to accurately forecast and, as a result, we may be unable to optimally match production with customer demand, which could adversely affect our business and financial results.

We make planning and spending decisions, including determining the levels of business that we will seek and accept, production schedules, inventory levels, component procurement commitments, personnel needs and other resource requirements, based on our estimates of customer requirements. The short-term nature of commitments by many of our customers and the possibility of unexpected changes in demand for their products reduce our ability to accurately estimate future customer requirements. On occasion, customers may require rapid increases in production, which can strain our resources, cause our manufacturing to be negatively impacted by materials shortages, necessitate higher or more restrictive procurement commitments, increase our manufacturing yield loss and scrapping of excess materials, and reduce our gross margin. We may not have sufficient capacity at any given time to meet the volume demands of our customers, or one or more of our suppliers may not have sufficient capacity at any given time to meet our volume demands. Conversely, a downturn in the markets in which our customers compete can cause, and in the past have caused, our customers to significantly reduce or delay

the amount of products ordered or to cancel existing orders, leading to lower utilization of our facilities. Because many of our costs and operating expenses are relatively fixed, reduction in customer demand due to market downturns or other reasons would have a negative effect on our gross margin, operating income and cash flow.

~~Customer orders~~

Rapidly changing standards and ~~forecasts are~~regulations could make our products obsolete, which would cause our revenue and results of operations to suffer.

We design products to conform to our customers’ requirements and our customers’ systems may be subject to ~~cancellation~~regulations established by governments or ~~modification at any time which could result in higher manufacturing costs.~~

~~Our sales~~industry standards bodies worldwide. Because some of our products are ~~made primarily pursuant~~designed to ~~standard purchase orders for delivery of products. However, by~~conform to current specific industry ~~practice, some orders may be canceled~~standards, if competing or ~~modified at any time. When a customer cancels an order, they~~new standards emerge that are responsible for all finished goods, all costs, direct and indirect, incurred by us, as well as a reasonable allowance for anticipated profits. No assurance can be given that we will receive these amounts after cancellation. Furthermore, uncertainty in customer forecasts of their demands and other factors may lead to delays and disruptions in manufacturing, which could result in delays in product shipments to customers and could adversely affect our business.

Fluctuations and changes in customer demand are common in our business. Such fluctuations, as well as quality control problems experienced in manufacturing operations, may cause delays and disruptions in our manufacturing process and overall operations and reduce output capacity. As a result, product shipments could be delayed beyond the shipment schedules requestedpreferred by our customers, we would have to make significant expenditures to develop new products. If our customers adopt new or ~~could be canceled,~~ competing industry standards with

Table of Contents

which our products are not compatible, or the industry groups adopt standards or governments issue regulations with which our products are not compatible, our existing products would ~~negatively affect~~become less desirable to our ~~sales, operating income, strategic position at~~ customers ~~market share~~ and ~~reputation. In addition, disruptions, delays or cancellations could cause inefficient production which in turn could result in higher manufacturing costs, lower yields~~our revenue and ~~potential excess and obsolete inventory or manufacturing equipment. In the past, we have experienced such delays, disruptions and cancellations.~~results of operations would suffer.

The results of our operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers’ businesses and levels of business activity.

Global economic and political conditions affect our customers’ businesses and the markets they serve. A severe or prolonged economic downturn, including during and following the COVID-19 pandemic, or a negative or uncertain political climate could adversely affect our customers’ financial conditions and the timing or levels of business activity of our customers and the industries we serve. This may reduce the demand for our products or depress pricing for our products and have a material adverse effect on our results of operations. Changes in global economic conditions could also shift demand to products or services for which we do not have competitive advantages, and this could negatively affect the amount of business we are able to obtain. For example, inflation rates, particularly in the United States, the United Kingdom and Germany, have increased recently to levels not seen in years, and increased inflation may result in decreased demand for our products, increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital. In addition, the Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks. Additionally, financial markets around the world have experienced volatility in connection with the current hostilities between Russia and the Ukraine and the Israel-Hamas war. In addition, if we are unable to successfully anticipate changing economic and political conditions, we may be unable to effectively plan for and respond to those changes, and our business could be negatively affected as a result.

We have ~~a history of~~experienced net losses in the past, and because our strategy for expansion may be costly to implement, we may experience ~~continuing~~ losses and may ~~never achieve or~~not maintain profitability or positive cash flow.

We ~~realized a~~have experienced net ~~loss from continuing operations of $0.3 million and $3.0 million for~~losses in the ~~nine months ended September 30, 2017 and 2016, respectively.~~past. We expect to continue to incur significant expenses as we pursue our strategic initiatives, including increased expenses for research and development, sales and marketing and manufacturing. We may also grow our business in part through acquisitions of additional companies and complementary technologies which could cause us to incur greater than anticipated transaction expenses, amortization or write-offs of intangible assets and other acquisition-related expenses. As a result, we may incur net losses ~~for~~in the ~~foreseeable~~ future, and these losses could be substantial. At a certain level, continued net losses could impair our ability to comply with ~~NASDAQ~~Nasdaq continued listing standards, as described further below.

Our ability to generate additional revenue and remain profitable will depend on our ability to execute our key growth initiative regarding the development, marketing and sale of sensing products, develop and commercialize innovative technologies, expand our contract research capabilities and sell the products that result from those development initiatives. We may not be able to sustain or increase our profitability on a quarterly or annual basis.

We have obtained capital by borrowing money under a term ~~loans~~loan and revolving line of credit and we might require additional capital to support and expand our business; our term loan ~~has~~and revolving line of credit have various ~~loan~~ covenants with which we must comply.

We intend to continue to make investments to support our business growth, including developing new products, enhancing our existing products, obtaining important regulatory approvals, enhancing our operating infrastructure, completing our development activities and building our commercial scale manufacturing facilities. To the extent that we are unable to ~~become or~~ remain profitable and to finance our activities from continuing operations, we may require additional funds to support these initiatives and to grow our business.

If we are successful in raising additional funds through issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, including as the result of the issuance of warrants in connection with the financing, and any new equity securities we issue could have rights, preferences and privileges superior to those of our existing common stock. Furthermore, such financings may jeopardize our ability to apply for SBIR grants or qualify for SBIR contracts or grants, and our dependence on SBIR grants may restrict our ability to raise additional outside capital. If we raise additional

funds through debt financings, these financings may involve significant cash payment obligations and covenants that restrict our ability to operate our business and make distributions to our stockholders.

We have a term ~~loans~~loan and borrowings under a revolving line of credit with ~~Silicon Valley~~PNC Bank, National Association ("~~SVB"~~PNC"), which ~~requires~~require us to ~~observe certain financial~~comply with a number of affirmative and ~~operational~~restrictive covenants including, among others, financial covenants regarding minimum net leverage and fixed charge coverage, affirmative covenants regarding delivery of financial statements, payment of taxes, and maintenance of ~~a minimum cash balance~~government compliance, and restrictive covenants regarding dispositions of ~~$4.0 million, protection~~property, acquisitions, incurrence of additional indebtedness or liens, investments and ~~registration~~transactions with affiliates. We are also restricted from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions. Upon the

Table of Contents

occurrence of ~~intellectual property rights,~~certain events, including our failure to satisfy its payment obligations, failure to adhere to the financial covenants, the breach of certain of our other covenants, cross defaults to other indebtedness or material agreements, judgment defaults and ~~certain customary negative covenants, as well as~~defaults related to failure to maintain governmental approvals, PNC will have the right, among other ~~customary events of default. If any event of default occurs SVB may~~remedies, to declare all principal and interest immediately due ~~immediately all borrowings under our term loans~~ and ~~foreclose on the collateral. Furthermore, an event of default would result in an increase in the interest rate on any amounts outstanding.~~payable, and to exercise secured party remedies.

If we are unable to obtain adequate financing or financing terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be significantly limited.

~~Our nanotechnology-enabled products are new and may be, or may be perceived as being, harmful to human health or the environment.~~

While we believe that none of our current products contain chemicals known by us to be hazardous or subject to environmental regulation, it is possible that our current or future products, particularly carbon-based nanomaterials, may become subject to environmental or other regulation. We intend to develop and sell carbon-based nanomaterials as well as nanotechnology-enabled products, which are products that include nanomaterials as a component to enhance those products’ performance. Nanomaterials and nanotechnology-enabled products have a limited historical safety record. Because of their size or shape or because they may contain harmful elements, such as gadolinium and other rare-earth metals, our products could pose a safety risk to human health or the environment. These characteristics may also cause countries to adopt regulations in the future prohibiting or limiting the manufacture, distribution or use of nanomaterials or nanotechnology-enabled products. Such regulations may inhibit our ability to sell some products containing those materials and thereby harm our business or impair our ability to develop commercially viable products.

The subject of nanotechnology has received negative publicity and has aroused public debate. Government authorities could, for social or other purposes, prohibit or regulate the use of nanotechnology. Ethical and other concerns about nanotechnology could adversely affect acceptance of our potential products or lead to government regulation of nanotechnology-enabled products.

We face and will face substantial competition in several different markets that may adversely affect our results of operations.

We face and will face substantial competition from a variety of companies in several different markets. As we focus on developing marketing and selling fiber optic sensing products, we may also face substantial and entrenched competition in that market.

Many of our competitors have longer operating histories, greater name recognition, larger customer bases and significantly greater financial, sales and marketing, manufacturing, distribution, technical and other resources than we do. These competitors may be able to adapt more quickly to new or emerging technologies and changes in customer requirements. In addition, current and potential competitors have established or may establish financial or strategic relationships among themselves or with existing or potential customers or other third parties. Accordingly, new competitors or alliances among competitors could emerge and rapidly acquire significant market share. We cannot assure you that we will be able to compete successfully against current or new competitors, in which case our ~~revenues~~revenue may fail to increase or may decline.

Intense competition in our markets could result in aggressive business tactics by our competitors, including aggressively pricing their products or selling older inventory at a discount. If our current or future competitors utilize aggressive business tactics, including those described above, demand for our products could decline, we could experience delays or cancellations of customer orders, or we could be required to reduce our sales prices.

~~Decreases in average selling prices of our products may increase operating losses and net losses, particularly if we are not able to reduce expenses commensurately.~~

The market for optical components and subsystems continues to be characterized by declining average selling prices resulting from factors such as increased price competition among optical component and subsystem manufacturers, excess capacity, the introduction of new products and increased unit volumes as manufacturers continue to deploy network and storage systems. In recent years, we have observed a significant decline of average selling prices, primarily in the telecommunications market. We anticipate that average selling prices will continue to decrease in the future in response to product introductions by competitors or by us, or in response to other factors, including price pressures from significant customers. In order to sustain profitable operations, we must, therefore, reduce the cost of our current designs or continue to develop and introduce new

~~products on a timely basis that incorporate features that can be sold at higher average selling prices. Failure to do so could cause our sales to decline and operating losses to increase.~~

Our cost reduction efforts may not keep pace with competitive pricing pressures. To remain competitive, we must continually reduce the cost of manufacturing our products through design and engineering changes. We may not be successful in redesigning our products or delivering our products to market in a timely manner. We cannot assure you that any redesign will result in sufficient cost reductions enabling us to reduce the price of our products to remain competitive or positively contribute to operating results.

Shifts in product mix may result in declines in gross profit.

Our gross profit margins vary among our product platforms and are generally highest on our test &and measurement instruments. Our overall gross profit may fluctuate from period to period as a result of a variety of factors including shifts in product mix, the introduction of new products, and decreases in average selling prices for older products. If our customers decide to buy more of our products with low gross profit margins or fewer of our products with high gross profit margins, our total gross profits could be harmed.

~~Risks Relating~~RISKS RELATING TO OUR OPERATIONS AND BUSINESS STRATEGY

If we fail to properly evaluate and execute our ~~Operations~~strategic initiatives, including the integration of acquired businesses, it could have an adverse effect on our future results and ~~Business Strategy~~the market price of our common stock.

We evaluate strategic opportunities related to products, technology and business transactions, including acquisitions and divestitures. In the past, we have acquired businesses to support our growth strategy, including the acquisition of Lios in March 2022. If we choose to enter into such transactions in the future, we face certain risks including:

•the failure of the acquired business to meet our performance and financial expectations;

•difficulty integrating an acquired business's operations, personnel and financial and reporting systems into our current business

•potential unknown liabilities associated with the acquisition;

•lost sales and customers as a result of customers deciding not to do business with us;

•complexities associated with managing the larger combined company with distant business locations;

•integrating personnel while maintaining focus on providing consistent, high quality products;

•loss of key employees; and

•performance shortfalls as a result of the division of management's attention caused by completing the acquisition and integrating operations.

If any of these events were to occur, our ability to maintain relationships with the customers, suppliers and employees or our ability to achieve the anticipated benefits of the acquisition could be adversely affected, or could reduce our future earnings

Table of Contents

or otherwise adversely affect our business and financial results and, as a result, adversely affect the market price of our common stock.

If we cannot successfully transition our revenue mix from contract research ~~revenues~~revenue to product sales and license ~~revenues,~~revenue, we may not be able to fully execute our business model or grow our business.

Our business model and future growth depend on our ability to transition to a revenue mix that contains significantly larger product sales and ~~revenues~~revenue from the provision of services or from licensing. Product sales and ~~these revenues~~license revenue potentially offer greater scalability than contract research ~~revenues.~~revenue. Our current plan is to increase our sales of commercial products, our licensing ~~revenues~~revenue and our provision of non-research services to customers so as to represent a larger percentage of our total ~~revenues.~~revenue. If we are unable to develop and grow our product sales and ~~revenues~~revenue from the provision of services or from licensing to augment our contract research ~~revenues,~~revenue, however, our ability to execute our business model or grow our business could suffer. There can be no assurance that we will be able to achieve increased ~~revenues~~revenue in this manner.

Failure to develop, introduce and sell new products or failure to develop and implement new technologies, could adversely impact our financial results.

Our success will depend on our ability to develop and introduce new products that customers choose to buy. The new products the market requires tend to be increasingly complex, incorporating more functions and operating at faster speeds than old products. If we fail to introduce new product designs or technologies in a timely manner or if customers do not successfully introduce new systems or products incorporating our products, , our business, financial condition and results of operations could be materially harmed.

If we are unable to manage growth effectively, our ~~revenues~~revenue and net loss could be adversely affected.

We may need to expand our personnel resources to grow our business effectively. We believe that sustained growth at a higher rate will place a strain on our management as well as on our other human resources. To manage this growth, we must continue to attract and retain qualified management, professional, scientific and technical and operating personnel. If we are unable to recruit a sufficient number of qualified personnel, we may be unable to staff and manage projects adequately, which in turn may slow the rate of growth of our contract research ~~revenues~~revenue or our product development efforts.

We may not be successful in identifying market needs for new technologies or in developing new products.

Part of our business model depends on our ability to correctly identify market needs for new technologies. We intend to identify new market needs, but we may not always have success in doing so in part because our contract research largely centers on identification and development of unproven technologies, often for new or emerging markets. Furthermore, we must identify the most promising technologies from a sizable pool of projects. If our commercialization strategy process fails to identify projects with commercial potential or if management does not ensure that such projects advance to the commercialization stage, we may not successfully commercialize new products and grow our ~~revenues.~~revenue.

Our growth strategy requires that we also develop successful commercial products to address market needs. We face several challenges in developing successful new products. Many of our existing products and those currently under development are technologically innovative and require significant and lengthy product development efforts. These efforts

include planning, designing, developing and testing at the technological, product and manufacturing-process levels. These activities require us to make significant investments. Although there are many potential applications for our technologies, our resource constraints require us to focus on specific products and to forgo other opportunities. We expect that one or more of the potential products we choose to develop will not be technologically feasible or will not achieve commercial acceptance, and we cannot predict which, if any, of our products we will successfully develop or commercialize. The technologies we research and develop are new and steadily changing and advancing. The products that are derived from these technologies may not be applicable or compatible with the state of technology or demands in existing markets. Our existing products and technologies may become uncompetitive or obsolete if our competitors adapt more quickly than we do to new technologies and changes in customers’ requirements. Furthermore, we may not be able to identify if and when new markets will open for our products given that future applications of any given product may not be readily determinable, and we cannot reasonably estimate the size of any markets that may develop. If we are not able to successfully develop new products, we may be unable to increase our product ~~revenues.~~revenue.

Table of Contents

We face risks associated with our international business.

We currently conduct business internationally and we might considerably expand our international activities in the future. Our international business operations are subject to a variety of risks associated with conducting business internationally, including:

•having to comply with U.S. and other export control and economic trade sanctions regulations and policies that restrict ~~our ability to communicate with~~certain operations and work involving non-U.S. employees and sale and supply of our products to foreign ~~affiliates and~~ customers;

•changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products, perform services or repatriate profits to the United States;

•the imposition of tariffs;

•hyperinflation or economic or political instability in foreign countries;

•imposition of limitations on, or increase of withholding and other taxes on remittances and other payments by foreign subsidiaries or joint ventures;

•conducting business in places where business practices and customs are unfamiliar and unknown;

•the imposition of restrictive trade policies;

•the imposition of inconsistent laws or regulations;

•the imposition or increase of investment and other restrictions or requirements by foreign governments;

•uncertainties relating to foreign laws and legal proceedings;

•potential changes in a specific country's or region's political or economic climate, including the current hostilities between Russia and Ukraine and the Israel-Hamas war;

•having to comply with ~~a variety of U.S.~~anti-corruption and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act ("FCPA");, the UK Bribery Act 2010, and similar laws and regulations in other jurisdiction; and

•having to comply with licensing requirements.

We do not know the impact that these regulatory, geopolitical and other factors may have on our international business in the future. It is unknown how global supply chains may continue to be affected from the COVID-19 pandemic.

We may dispose of or discontinue existing product lines and technology developments, which may adversely impact our future results.

On an ongoing basis, we evaluate our various product offerings and technology developments in order to determine whether any should be discontinued or, to the extent possible, divested. ~~For example, we recently sold our HSOR business to a third party.~~ In addition, if we are unable to generate the amount of cash needed to fund the future operations of our business, we may be forced to sell one or more of our product lines or technology developments.

We cannot guarantee that we have correctly forecasted, or that we will correctly forecast in the future, the right product lines and technology developments to dispose or discontinue or that our decision to dispose of or discontinue various investments, ~~products~~product lines and technology developments is prudent if market conditions change. In addition, there are no assurances that the discontinuance of various product lines will reduce operating expenses or will not cause us to incur material charges associated with such decision. Furthermore, the discontinuance of existing product lines entails various risks, including the risk that we will not be able to find a purchaser for a product line or the purchase price obtained will not be equal to at least the book value of the net assets for the product line. Other risks include managing the expectations of, and maintaining good relations with, our historical customers who previously purchased products from a disposed or discontinued product line, which could prevent us from selling other products to them in the future. We may also incur other significant liabilities and costs associated with disposal or discontinuance of product lines, including employee severance costs and excess facilities costs.

We are experiencing impacts from inflationary pressures, including with respect to labor and materials costs, which could adversely impact our profitability and cash flow.

We are experiencing, and may continue to experience, the general impact of inflationary market pressures on our business, particularly with respect to labor and materials costs. We are experiencing pressures on materials and certain labor costs as a result of the inflationary environment and current general labor shortage, which has resulted in increased competition

Table of Contents

for skilled labor and wage inflation. It is possible that our labor, fuel and materials costs could continue to increase as we expand our operations and volume of work. We have not been, and may not be ~~liable~~able to, fully adjust our contract pricing to compensate for ~~damages based on product liability claims relating~~these cost increases, which has affected, and may continue to ~~defects~~affect, our profitability and cash flows. Inflationary pressures and related recessionary concerns in ~~our products, which might be brought against us directly, or against our customers in their end-use markets. Such claims~~light of governmental and central bank efforts to mitigate inflation could ~~result in a loss of customers in addition to substantial liability in damages.~~

~~Our products are complex and undergo quality testing as well as formal qualification, both by~~also cause uncertainties for our customers and affect the level of their project activity, which could also adversely affect our profitability and cash flows.

Health epidemics, including the COVID-19 pandemic, have had, and could in the future have, an adverse impact on our business, operations, and the markets and communities in which we and our customers and suppliers operate.

The ongoing global COVID-19 pandemic has impacted, and will likely continue to impact, the way we conduct our business, including the way in which we interface with customers, suppliers and our employees. The COVID-19 pandemic has affected how we interact with our customers by ~~us. However, defects may occur from time to time. Our customers’ testing procedures may be limited to evaluating~~reducing face-to-face meetings and increasing our ~~products under likely~~on-line and ~~foreseeable failure scenarios~~virtual presence. While increasing our on-line and ~~over varying amounts of time. For various reasons, such as the occurrence of performance problems that~~virtual presence has proven effective, we are unforeseeable in testing or that are detected only when products age or are operated under peak stress conditions, our products may fail to perform as expected long after customer acceptance. Failures could result from faulty components or design, problems in manufacturing or other unforeseen reasons. As a result, we could incur significant costs to repair or replace defective products under warranty, particularly when such failures occur in installed systems. In addition, we may in certain circumstances honor warranty claims after the warranty has expired or for problems not covered by warranty in order to maintain customer relationships. Any significant product failure could result in lost future salesunsure of the ~~affected product~~impact if these conditions continue for an extended period. During 2021 and ~~other products, as well as customer relations problems, litigation~~2022, we experienced an increased level of disruption in our supply chain and ~~damage to our reputation.~~

In addition, many of our products are embedded in, or deployed in conjunction with, our customers’ products, which incorporate a variety of components, modules and subsystems and may be expected to interoperate with modules produced by third parties. As a result, not all defects are immediately detectable, and, when problems occur, it may be difficult to identify the source of the problem. These problems may cause us to incur significant damages or warranty and repair costs, divert the attention of our engineering personnel from ~~internal product development efforts and cause significant customer relations problems or loss of~~certain customers all of which ~~would harm our business.~~

~~Furthermore, many of~~have resulted in delayed revenue. While we believe these disruptions are temporary, there is no guarantee we will be able to manage through these disruptions. If the demand for our products, ~~may provide~~or our access to critical performance attributes to our customers’ products that will be sold to end users who could potentially bring product liability suits in which we could be named as a defendant. The sale of these products involves the risk of product liability claims. If a personcomponents were to bring a product liability suit against one of our customers, this customer may attempt to seek contribution from us. A person may also bring a product liability claim directly against us. A successful product liability claim or series of claims against us in excess of our insurance coverage for payments, for which we are not otherwise indemnified,be interrupted, it could have a material adverse ~~effect on our financial condition or results of operations.~~

~~We could be negatively affected by a security breach, either through cyber-attack, cyber-intrusion or other significant disruption of our IT networks and related systems.~~

We face the risk, as does any company, of a security breach, whether through cyber-attack or cyber-intrusion over the internet, malware, computer viruses, attachments to e-mails, persons inside our organization or persons with access to systems inside our organization, or other significant disruption of our IT networks and related systems. The risk of a security breach or disruption, particularly through cyber-attack or cyber-intrusion, including by computer hackers, foreign governments and cyber terrorists, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.

As a technology company, and particularly as a government contractor, we may face a heightened risk of a security breach or disruption from threats to gain unauthorized access to our proprietary, confidential or classified information on our IT networks and related systems. These types of information and IT networks and related systems are critical to the operation of our business and essential to our ability to perform day-to-day operations, and, in some cases, are critical to the operations of certain of our customers. In addition, as certain of our technological capabilities become widely known, it is possible that we may be subjected to cyber-attack or cyber-intrusion as third parties seek to gain improper access to information regarding these capabilities and cyber-attacks or cyber-intrusion could compromise our confidential information or our IT networks and systems generally, as it is not practical as a business matter to isolate all of our confidential information and trade secrets from email and internet access. There can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damaging.

A security breach or other significant disruption involving these types of information and IT networks and related systems could disrupt the proper functioning of these networks and systems and therefore our operations, compromise our confidential information and trade secrets, or damage our reputation among our customers and the public generally. Any of these developments could have a negative impact on our results of operations.

In response to the COVID-19 pandemic, many state, local, and foreign governments have put in place, and others in the future may put in place, quarantines, executive orders, shelter-in-place orders, and similar government orders and restrictions in order to control the spread of the disease. Such orders or restrictions, or the perception that such orders or restrictions could occur, have resulted in business closures, work stoppages, slowdowns and delays, work-from-home policies, travel restrictions, and cancellation or postponement of events, among other effects that could negatively impact productivity and disrupt our operations ~~financial condition~~ and ~~cash flows.~~

~~Risks Relating~~those of our customers and suppliers. We have implemented alternate work arrangements, including staggered schedules and shifts, distancing within our offices and working from home for most of our employees, and we may take further actions that alter our operations as may be required by federal, state, or local authorities, or which we determine are in our best interests. While most of our operations can be performed under these alternate work arrangements, there is no guarantee that we will be as effective while working under them because our team is dispersed, many employees may have additional personal needs to attend to (such as looking after children as a result of school closures or family who become sick), and employees may become sick themselves and be unable to work. Decreased effectiveness of our team could adversely affect our results due to our ~~Regulatory Environment~~inability to meet in person with potential customers, longer time periods for supply, longer time periods for manufacturing and other decreases in productivity that could seriously harm our business.

In addition, while the potential impact and duration of the COVID-19 pandemic on the global economy and our business in particular may be difficult to assess or predict, the pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital, which could negatively affect our liquidity in the future.

The global impact of COVID-19 continues to rapidly evolve, and we will continue to monitor the situation closely. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, operations, or the global economy as a whole. While the spread of COVID-19 may eventually be contained or mitigated, there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur, or that the global economy will recover, either of which could seriously harm our business.

RISKS RELATING TO OUR REGULATORY ENVIRONMENT

Our operations are subject to domestic and foreign laws, regulations and restrictions, and noncompliance with these laws, regulations and restrictions could expose us to fines, penalties, suspension or debarment, which could have a material adverse effect on our profitability and overall financial position.

Our operations, particularly our international sales, subject us to numerous U.S. and foreign laws and regulations, including, without limitation, regulations relating to imports, exports (including the Export Administration Regulations and the

International Traffic in Arms Regulations), technology transfer restrictions, anti-boycott provisions, economic sanctions and anti-corruption.

Our products and solutions are subject to export control and import laws and regulations, including the ~~FCPA. The number~~U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations (ITAR), U.S. Customs regulations, and the economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls.

Table of Contents

Exports of our ~~various emerging~~products, services, and technology must be made in compliance with these laws and regulations, and in some cases, certain registration, licensing, authorization, or reporting requirements may need to be performed. In addition, these laws may restrict or prohibit altogether the sale or supply of certain of our products, services, and technologies to certain governments, persons, entities, countries, and territories, including those that are the ~~development~~target of ~~many~~comprehensive sanctions, unless there are license exceptions that apply or specific licenses are obtained. Any future changes in export control, import, or economic sanctions laws and regulations may adversely impact our ability to sell our products, services, and technologies in certain markets or, in some cases, prevent the export or import of our products, services, and technologies to or from certain countries, governments, or persons altogether, which ~~has~~could adversely affect our business, results of operations, and growth prospects.

Our products, services, and technologies may have in the past been ~~funded by~~provided, and could in the ~~Department~~future be provided, in violation of ~~Defense, presents~~export control, import, or sanctions laws and regulations, despite the precautions we take. As a result, we have submitted, and from time to time may continue to submit as warranted, voluntary self-disclosures regarding compliance with U.S. export control and sanctions laws and regulations to relevant governmental authorities. Any failure to comply with applicable export control and sanctions laws may materially affect us ~~with many regulatory challenges.~~ through reputational harm, as well as other negative consequences, including government investigations, substantial civil or criminal penalties, and possible loss of export or import privileges.

We are also subject to the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, the Proceeds of Crime Act 2002, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, third-party intermediaries, and other associated persons from authorizing, promising, offering, providing, soliciting, or accepting directly or indirectly, improper payments or benefits to or from any person whether in the public or private sector. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, representatives, contractors, business partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.

Failure by us or our sales representatives or consultants to comply with ~~these~~the above laws and regulations could result in administrative, civil, or criminal liabilities and could result in suspension of our export privileges, which could have a material adverse effect on our business. Changes in regulation or political environment may affect our ability to conduct business in foreign markets including investment, procurement and repatriation of earnings.

Environmental regulations could increase operating costs and additional capital expenditures and delay or interrupt operations.

The photonics industry, as well as the semiconductor industry, are subject to governmental regulations for the protection of the environment, including those relating to air and water quality, solid and hazardous waste handling, and the promotion of occupational safety. Various federal, state and local laws and regulations require that we maintain certain environmental permits. While we believe that we have obtained all necessary environmental permits required to conduct our manufacturing processes, if we are found to be in violation of these laws, we could be subject to governmental fines and liability for damages resulting from such violations.

Changes in the aforementioned laws and regulations or the enactment of new laws, regulations or policies could require increases in operating costs and additional capital expenditures and could possibly entail delays or interruptions of our operations.

If our manufacturing facilities do not meet Federal, state or foreign country manufacturing standards, we may be required to temporarily cease all or part of our manufacturing operations, which would result in product delivery delays and negatively impact ~~revenues.~~revenue.

Our manufacturing facilities are subject to periodic inspection by regulatory authorities and our operations will continue to be regulated by the FDA for compliance with Good Manufacturing Practice requirements contained in the quality systems regulations. We are also required to comply with International Organization for Standardization ("ISO"), quality system standards in order to produce certain of our products for sale in Europe. If we fail to continue to comply with Good Manufacturing Practice requirements or ISO standards, we may be required to cease all or part of our operations until we comply with these regulations. Obtaining and maintaining such compliance is difficult and costly. We cannot be certain that our facilities will be found to comply with Good Manufacturing Practice requirements or ISO standards in future inspections and audits by regulatory authorities. In addition, if we cannot maintain or establish manufacturing facilities or operations that comply with such standards or do not meet the expectations of our customers, we may not be able to realize certain economic opportunities in our current or future supply arrangements.

Medical products are subject to various international regulatory processes and approval requirements. If we do not obtain and maintain the necessary international regulatory approvals for any such potential products, we may not be able to market and sell our medical products in foreign countries.

~~To be able to market and sell medical products in other countries, we must obtain regulatory approvals and comply with the regulations~~

Table of those countries. These regulations, including the requirements for approvals and the time required for regulatory review, vary from country to country. Obtaining and maintaining foreign regulatory approvals are expensive, and we cannot be certain that we will have the resources to be able to pursue such approvals or whether we would receive regulatory approvals in any foreign country in which we plan to market our products. For example, the European Union requires that manufacturers of medical products obtain the right to affix the CE mark to their products before selling them in member countries of the European Union, which we have not yet obtained and may never obtain. If we fail to obtain regulatory approval in any foreign country in which we plan to market our products, our ability to generate revenues will be harmed. Contents

We are subject to additional significant foreign and domestic government regulations, including environmental and health and safety regulations, and failure to comply with these regulations could harm our business.

Our facilities and current and proposed activities involve the use of a broad range of materials that are considered hazardous under applicable laws and regulations. Accordingly, we are subject to a number of foreign, federal, state and local laws and regulations relating to health and safety, protection of the environment and the storage, use, disposal of, and exposure to, hazardous materials and wastes. We could incur costs, fines and civil and criminal penalties, personal injury and ~~third party~~third-party property damage claims, or could be required to incur substantial investigation or remediation costs, if we were to violate or become liable under environmental, health and safety laws. Moreover, a failure to comply with environmental laws could result

in fines and the revocation of environmental permits, which could prevent us from conducting our business. Liability under environmental laws can be joint and several and without regard to fault. There can be no assurance that violations of environmental and health and safety laws will not occur in the future as a result of the inability to obtain permits, human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could harm our business. Accordingly, violations of present and future environmental laws could restrict our ability to expand facilities, pursue certain technologies, and could require us to acquire costly equipment or incur potentially significant costs to comply with environmental regulations.

Compliance with foreign, federal, state and local environmental laws and regulations represents a small part of our present budget. If we fail to comply with any such laws or regulations, however, a government entity may levy a fine on us or require us to take costly measures to ensure compliance. Any such fine or expenditure may adversely affect our development. We cannot predict the extent to which future legislation and regulation could cause us to incur additional operating expenses, capital expenditures or restrictions and delays in the development of our products and properties.

~~Risks Relating~~We are or may become subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.

In the ordinary course of business we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing) personal data and other sensitive information, including proprietary and confidential business data, intellectual property, sensitive third-party data, business plans, and transactions (collectively, sensitive data) in connection with our business customers and our employees.

Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.

In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).

For example, the California Consumer Privacy Act, or the CCPA, requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation, as well as a private right of action for individuals affected by certain data breaches to recover significant statutory damages. Additionally, the California Privacy Rights Act, or CPRA, which became effective on January 1, 2023, expands the CCPA’s requirements, including applying to personal information of business representatives and employees and creating a new regulatory agency that will be vested with authority to implement and enforce the CCPA and the CPRA.

Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. These developments may further complicate compliance efforts, and may increase legal risk and compliance costs for us and the third parties upon whom we rely. Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, under the European Union’s General Data Protection Regulation, or EU GDPR, and the United Kingdom’s so-called ‘UK GDPR’ companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR / 17.5 million pounds sterling under the UK GDPR or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.

In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the

Table of Contents

European Economic Area, or EEA, and the United Kingdom, or UK, have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK’s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data to recipients outside Europe for allegedly violating the EU GDPR’s cross-border data transfer limitations. Additionally, companies that transfer personal data to recipients outside of the EEA and/or UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators individual litigants and activist groups.

In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.

We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.

Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations may require us to; modify our data processing practices and policies; put in place additional mechanisms ensuring compliance with the new data protection rules; divert resources from other initiatives and projects; and restrict the way products and services involving data are offered, all of which could significantly harm our business, financial condition, results of operations and prospects.

Further, compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with any such laws or regulations, which could adversely affect our business, financial condition and results of operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our ~~Intellectual Property~~business model or operations.

RISKS RELATING TO OUR INTELLECTUAL PROPERTY

Our proprietary rights may not adequately protect our technologies.

Our commercial success will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection of our technologies in the United States and other jurisdictions as well as successfully enforcing this intellectual property and defending it against third-party challenges. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable intellectual property protections, such as patents or trade secrets, cover them. In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant new technologies, products and processes. The degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. The degree of future protection of our proprietary rights is also uncertain for products that are currently in the early stages of development because we cannot predict which of these products will ultimately reach the commercial market or whether the commercial versions of these products will incorporate proprietary technologies.

Table of Contents

Our patent position is highly uncertain and involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example:

•we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;

•we or our licensors might not have been the first to file patent applications for these inventions;

•others may independently develop similar or alternative technologies or duplicate any of our technologies;

•it is possible that none of our pending patent applications or the pending patent applications of our licensors will result in issued patents;

•patents may issue to third parties that cover how we might practice our technology;

•our issued patents and issued patents of our licensors may not provide a basis for commercially viable technologies, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and

•we may not develop additional proprietary technologies that are patentable.

Patents may not be issued for any pending or future pending patent applications owned by or licensed to us, and claims allowed under any issued patent or future issued patent owned or licensed by us may not be valid or sufficiently broad to protect our technologies. Moreover, protection of certain of our intellectual property may be unavailable or limited in the United States or in foreign countries, and we have not sought to obtain foreign patent protection for certain of our products or technologies due to cost, concerns about enforceability or other reasons. Any issued patents owned by or licensed to us now or in the future may be challenged, invalidated, or circumvented, and the rights under such patents may not provide us with competitive advantages. In addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in some foreign countries, and in the case of certain products no foreign patents were filed or can be filed. This could make it easier for competitors to capture or increase their market share with respect to related technologies. We could incur substantial costs to bring suits in which we may assert our patent rights against others or defend ourselves in suits brought against us. An unfavorable outcome of any litigation could have a material adverse effect on our business and results of operations.

We also rely on trade secrets to protect our technology, especially where we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. We regularly attempt to obtain confidentiality agreements and contractual provisions with our collaborators, employees and consultants to protect our trade secrets and proprietary know-how. These agreements may be breached or may not have adequate remedies for such breach. While we use reasonable efforts to

protect our trade secrets, our employees, consultants, contractors or scientific and other advisors, or those of our strategic partners, may unintentionally or willfully disclose our information to competitors. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, our enforcement efforts would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States are sometimes unwilling to protect trade secrets. Moreover, if our competitors independently develop equivalent knowledge, methods and know-how, it will be more difficult for us to enforce our rights and our business could be harmed.

If we are not able to defend the patent or trade secret protection position of our technologies, then we will not be able to exclude competitors from developing or marketing competing technologies and we may not generate enough ~~revenues~~revenue from product sales to justify the cost of developing our technologies and to achieve or maintain profitability.

We also rely on trademarks to establish a market identity for our company and our products. To maintain the value of our trademarks, we might have to file lawsuits against third parties to prevent them from using trademarks confusingly similar to or dilutive of our registered or unregistered trademarks. Also, we might not obtain registrations for our pending trademark applications, and we might have to defend our registered trademark and pending trademark applications from challenge by third parties. Enforcing or defending our registered and unregistered trademarks might result in significant litigation costs and damages, including the inability to continue using certain trademarks.

Third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.

Various U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in our technology areas. Such third parties may claim that we infringe their patents. Because patent applications can take several years to result in a patent issuance, there may be currently pending applications, unknown to us, which may later result in issued patents that our technologies may infringe. For example, we are aware of competitors with patents in technology areas applicable to our optical test equipment products. Such competitors may allege that we infringe these patents. There could also be existing patents of which we are not aware that our technologies may inadvertently infringe. We have from time to time been, and may in the future be, contacted by third parties, including patent assertion entities or intellectual property advisors, about licensing opportunities that also contain claims that we are infringing on third party patent rights. If third parties assert these claims against us, we could incur extremely substantial costs and diversion of management resources in defending these

Table of Contents

claims, and the defense of these claims could have a material adverse effect on our business, financial condition and results of operations. Even if we believe we have not infringed on a third party’s patent rights, we may have to settle a claim on unfavorable terms because we cannot afford to litigate the claim. In addition, if third parties assert claims against us and we are unsuccessful in defending against these claims, these third parties may be awarded substantial damages as well as injunctive or other equitable relief against us, which could effectively block our ability to make, use, sell, distribute or market our products and services in the United States or abroad.

Commercial application of nanotechnologies in particular, or technologies involving nanomaterials, is new and the scope and breadth of patent protection is uncertain. Consequently, the patent positions of companies involved in nanotechnologies have not been tested, and there are complex legal and factual questions for which important legal principles will be developed or may remain unresolved. In addition, it is not clear whether such patents will be subject to interpretations or legal doctrines that differ from conventional patent law principles. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our nanotechnology-related intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our nanotechnology-related patents or in third party patents. In the event that a claim relating to intellectual property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture or distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.

A substantial portion of our technology is subject to retained rights of our licensors, and we may not be able to prevent the loss of those rights or the grant of similar rights to third parties.

A substantial portion of our technology is licensed from academic institutions, corporations and government agencies. Under these licensing arrangements, a licensor may obtain rights over the technology, including the right to require us to grant a license to one or more third parties selected by the licensor or that we provide licensed technology or material to third parties for non-commercial research. The grant of a license for any of our core technologies to a third party could have a material and adverse effect on our business. In addition, some of our licensors retain certain rights under the licenses, including the right to grant additional licenses to a substantial portion of our core technology to third parties for non-commercial academic and

research use. It is difficult to monitor and enforce such non-commercial academic and research uses, and we cannot predict whether the third-party licensees would comply with the use restrictions of such licenses. We have incurred and could incur substantial expenses to enforce our rights against them. We also may not fully control the ability to assert or defend those patents or other intellectual property which we have licensed from other entities, or which we have licensed to other entities.

In addition, some of our licenses with academic institutions give us the right to use certain technology previously developed by researchers at these institutions. In certain cases, we also have the right to practice improvements on the licensed technology to the extent they are encompassed by the licensed patents and are within our field of use. Our licensors may currently own and may in the future obtain additional patents and patent applications that are necessary for the development, manufacture and commercial sale of our anticipated products. We may be unable to agree with one or more academic institutions from which we have obtained licenses whether certain intellectual property developed by researchers at these academic institutions is covered by our existing licenses. In the event that the new intellectual property is not covered by our existing licenses, we would be required to negotiate a new license agreement. We may not be able to reach agreement with current or future licensors on commercially reasonable terms, if at all, or the terms may not permit us to sell our products at a profit after payment of royalties, which could harm our business.

Some of our patents may cover inventions that were conceived or first reduced to practice under, or in connection with, U.S. government contracts or other federal funding agreements. With respect to inventions conceived or first reduced to practice under ~~a federal funding~~such agreement, the U.S. government may retain a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention throughout the world. We may not succeed in our efforts to retain title in patents, maintain ownership of intellectual property or in limiting the U.S. government’s rights in our proprietary technologies and intellectual property when an issue exists as to whether such intellectual property was developed in the performance of ~~a federal funding~~such agreement or developed at private expense.

If we fail to obtain the right to use the intellectual property rights of others which are necessary to operate our business, and to protect their intellectual property, our business and results of operations will be adversely affected.

In the past, we have licensed certain technologies for use in our products. In the future, we may choose, or be required, to license technology or intellectual property from third parties in connection with the development of our products. We cannot assure you that third-party licenses will be available on commercially reasonable terms, if at all. Our competitors may be able to obtain licenses, or cross-license their technology, on better terms than we can, which could put us at a competitive disadvantage. Also, we often enter into confidentiality agreements with such third parties in which we agree to protect and maintain their proprietary and confidential information, including at times requiring our employees to enter into agreements protecting such information. There can be no assurance that the confidentiality agreements will not be breached by any of our employees or that such third parties will not make claims that their proprietary information has been disclosed.

Table of Contents

RISKS RELATING TO OUR COMMON STOCK

Our common stock price has been volatile and we expect that the price of our common stock will fluctuate substantially in the future, which could cause you to lose all or a substantial part of your investment.

The public trading price for our common stock is volatile and may fluctuate significantly. Since January 1, 2009, our common stock has traded between a high of $12.85 per share and a low of $0.26 per share. Among the factors, many of which we cannot control, that could cause material fluctuations in the market price for our common stock are:

•sales of our common stock by our significant stockholders, or the perception that such sales may occur;

•changes in earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ earnings estimates;

•quarterly variations in our or our competitors’ results of operations;

•challenges integrating our recent or future acquisitions, including the inability to realize any expected synergies;

•general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;

•announcements by us, or by our competitors, of acquisitions, new products, significant contracts, commercial relationships or capital commitments;

•pending or threatened litigation;

•any major change in our board of directors or management or any competing proxy solicitations for director nominees;

•changes in governmental regulations or in the status of our regulatory approvals;

•announcements related to patents issued to us or our competitors;

•a lack of, limited or negative industry or securities analyst coverage;

•health epidemics, including the COVID-19 pandemic;

•political, economic and social instability, including, for example, the military incursion of Russia into Ukraine, the Israel-Hamas war, terrorist activities and any disruption these events may cause to the broader global industrial economy;

•discussions of our company or our stock price by the financial and scientific press and online investor communities; and

•general developments in our industry.

In addition, the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating performance of those companies. These factors may materially and adversely affect the market price of our common stock.

If our estimates relating to our critical accounting policies are based on assumptions or judgments that change or prove to be incorrect, our operating results could fall below expectations of financial analysts and investors, resulting in a decline in our stock price.

The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates, assumptions and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. Our operating results may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our operating results to fall below the expectations of financial analysts and investors, resulting in a decline in our stock price. Significant assumptions and estimates used in preparing our consolidated financial statements include those related to revenue recognition, stock-based compensation and income taxes. Moreover, the revenue recognition guidance, ASC Topic 606, Revenue from Contracts with Customers, requires more judgment than did the prior guidance.

Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws and Delaware law could discourage or prevent a change in control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.

Our amended and restated certificate of incorporation and bylaws and Delaware law contain provisions that might delay or prevent a change in control, discourage bids at a premium over the market price of our common stock and adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. These provisions include:

•a classified board of directors serving staggered terms;

•advance notice requirements to stockholders for matters to be brought at stockholder meetings;

Table of Contents

•a supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws; and

•the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer.

We are also subject to provisions of the Delaware General Corporation law that, in general, prohibit any business combination with a beneficial owner of 15% or more of our common stock for three years unless the holder’s acquisition of our stock was approved in advance by our board of directors or certain other conditions are satisfied.

The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.

Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the U.S. federal district courts will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:

•anyderivativeclaimorcauseofactionbroughtonourbehalf;

•anyclaimorcauseofactionassertingabreachoffiduciaryduty;

•anyclaimorcauseofactionagainstusarisingunderDGCL;

•any claim or cause of action arisingunder orseeking tointerpretouramended andrestated certificate of incorporationorouramended and restated bylaws;and

•anyclaimorcauseofactionagainstusthatisgovernedbytheinternalaffairsdoctrine.

The provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws further provide that, unless we consent to the selection of an alternate forum, the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act.

While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.

These exclusive forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.

GENERAL RISK FACTORS

If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise.

In the ordinary course of our business, we and the third parties upon which we rely, face a variety of evolving cybersecurity related threats, including but not limited to phishing, malware, or ransomware attacks, which could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Any of these or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental

Table of Contents

acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our services.

As the numerous and evolving cybersecurity threats continue to become increasingly more complex and sophisticated, it becomes necessary for us to become cyber incident resilient. We have experienced security incidents in the past, and may do so in the future, resulting in the unauthorized, unlawful, or inappropriate access to sensitive and/or confidential data. For example, in January 2023, we detected a cyber incident impacting certain of our technology systems. Promptly upon our detection of the incident, we launched an investigation, notified federal law enforcement and engaged the services of incident response professionals (including a nationally recognized third-party forensic investigator) and specialized cybersecurity legal counsel. Where necessary, we disclosed the incident to customers in accordance with our contractual requirements regarding cyber incident disclosure. While we were able to manage this incident without any significant disruption to our operations, there is no guarantee that we will have similar success with other attacks in the future should one occur.

In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.

If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business.

While we have implemented security measures designed to protect against security incidents and take steps to become increasingly cyber incident resilient, there can be no assurance that these measures will be effective against an ever-evolving cyber threat landscape. We take steps designed to detect and mitigate vulnerabilities, but we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit the vulnerability change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. These vulnerabilities pose material risks to our business. While we maintain cyber insurance coverage to mitigate against the costs associated with a cyber incident, we cannot be certain that our cyber insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.

If there are substantial sales of our common stock, or the perception that such sales may occur, our stock price could decline.

If any of our stockholders were to sell substantial amounts of our common stock, the market price of our common stock may decline, which might make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate. Substantial sales of our common stock, or the perception that such sales may occur, may have a material adverse effect on the prevailing market price of our common stock.

Carilion Clinic holds approximately 3.5 million shares of our common stock (including approximately 1.3 million shares issuable to Carilion upon conversion of shares of Series A Convertible Preferred Stock that Carilion holds). All of these shares have been registered for sale on a Form S-3 registration statement and, accordingly, may generally be freely sold by Carilion at any time. Any sales of these shares, or the perception that future sales of shares may occur by Carilion or any of our other significant stockholders, may have a material adverse effect on the market price of our stock. Any such continuing material adverse effect on the market price of our stock could impair our ability to comply with NASDAQ’s continuing listing standards in respect of our minimum stock price, as further described below.

We may become involved in securities class action litigation that could divert management’s attention and harm our business and our insurance coverage may not be sufficient to cover all costs and damages.

The stock market has from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of technology companies. These broad market fluctuations may cause the market price of our common stock to decline. In the past, following periods of volatility in the market price of a particular company’s securities, securities class action litigation has often been brought against that company. Securities class litigation also often follows certain significant business transactions, such as the sale of a business division or a change in control transaction. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management’s attention and resources, which could adversely affect our business.

Table of Contents

We ~~may not be able~~are obligated to ~~comply with all applicable listing requirements or standards of The NASDAQ Capital Market~~develop and ~~NASDAQ could delist our common stock.~~

~~Our common stock is listed on The NASDAQ Capital Market. In order~~maintain proper and effective internal controls over financial reporting and any failure to maintain ~~that listing, we must satisfy minimum financial and other continued listing requirements and standards. One such requirement is that we maintain a minimum bid price~~the adequacy of at least $1.00 per share for our common stock. Although we currently comply with the minimum bid requirement, in the recent past, our minimum bid price has fallen below $1.00 per share, and it could again do so in the future. If our bid price falls below $1.00 per share for 30 consecutive business days, we will receive a deficiency notice from NASDAQ advising us that we have 180 days to regain compliance by maintaining a minimum bid price of at least $1.00 for a minimum of ten consecutive business days. Under certain circumstances, NASDAQ could require that the minimum bid price exceed $1.00 for more than ten consecutive days before determining that a company complies.

In the event that our common stock is not eligible for continued listing on NASDAQ or another national securities exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reductionthese internal controls may adversely affect investor confidence in our ~~coverage by security analysts~~company and, as a result, the ~~news media, which could cause the price of our common stock to decline further. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange.~~

The public trading price for our common stock is volatile and may fluctuate significantly. Since January 1, 2009, our common stock has traded between a high of $5.00 per share and a low of $0.26 per share. Among the factors, many of which we cannot control, that could cause material fluctuations in the market price for our common stock are:

~~sales of our common stock by our significant stockholders, or the perception that such sales may occur;~~

~~changes in earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ earnings estimates;~~

~~changes in our status as an entity eligible to receive SBIR contracts and grants;~~

~~quarterly variations in our or our competitors’ results of operations;~~

~~general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;~~

~~announcements by us, or by our competitors, of acquisitions, new products, significant contracts, commercial relationships or capital commitments;~~

~~pending or threatened litigation;~~

~~any major change in our board of directors or management or any competing proxy solicitations for director nominees;~~

~~changes in governmental regulations or in the status of our regulatory approvals;~~

~~announcements related to patents issued to us or our competitors;~~

~~a lack of, limited or negative industry or securities analyst coverage;~~

~~discussions of our company or our stock price by the financial and scientific press and online investor communities; and~~

~~general developments in our industry.~~

~~If our internal control over financial reporting is found not~~We are required, pursuant to be effective or if we make disclosure of existing or potential material weaknesses in those controls, investors could lose confidence in our financial reports, and our stock price may be adversely affected.

Section 404 of the Sarbanes-Oxley Act ~~of 2002 requires us~~ to ~~include an internal control~~furnish a report ~~with our Annual Report~~by management on, ~~Form 10-K. That report must include management’s assessment of~~among other things, the effectiveness of our internal control over financial reporting ason an annual basis. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting.

During the ~~end~~evaluation and testing process of ~~the fiscal year.~~

~~We evaluate~~ our ~~existing~~internal controls, if we identify one or more material weaknesses in our internal control over financial reporting, ~~based on the framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. During the course of~~we will be unable to assert that our ~~ongoing evaluation of the~~ internal ~~controls,~~control over financial reporting is effective. While we ~~may identify areas requiring improvement, and may~~ have ~~to design enhanced processes~~established certain procedures and controls ~~to address issues identified through this review. Remedying any deficiencies, significant deficiencies or material weaknesses that~~over our financial reporting processes, we ~~identify may require us to incur significant costs and expend significant time and management resources. We~~ cannot assure you that ~~any~~these efforts will prevent restatements of ~~the measures we implement to remedy any such deficiencies will effectively mitigate or remedy such deficiencies. Investors could lose confidence in~~ our financial ~~reports,~~statements in the future. We may not be able to remediate any future material weaknesses, or to complete our evaluation, testing and ~~our stock price may be adversely affected, if our~~any required remediation in a timely fashion.

Any failure to maintain internal ~~controls~~control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are ~~found not~~unable to beconclude that our internal control over financial reporting is effective, ~~by management or if~~ we ~~make disclosure~~could lose investor confidence in the accuracy and completeness of ~~existing or potential significant deficiencies or material weaknesses in those controls.~~

~~Anti-takeover provisions in~~ our amended and restated certificate of incorporation and bylaws and Delaware law could discourage or prevent a change in control, even if an acquisition would be beneficial to our stockholders, which could affect our stock price adversely and prevent attempts by our stockholders to replace or remove our current management.

~~Our amended and restated certificate of incorporation and bylaws and Delaware law contain provisions that might delay or prevent a change in control, discourage bids at a premium over~~financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.

The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions, including jurisdictions outside of the United States, could materially affect our tax obligations and effective tax rate. To the extent that such changes have a negative impact on us, our suppliers, manufacturers, or our customers, including as a result of related uncertainty, these changes may adversely ~~affect~~impact our business, financial condition, results of operations, and cash flows. For example, beginning in 2022, the ~~market price~~Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures immediately in the year incurred and requires taxpayers to amortize such expenditures over five years for tax purposes. While the most significant impact of this provision is to cash tax liability for 2022, the tax year in which the provision took effect, the impact will decline annually over the five-year amortization period to an immaterial amount in year six.

The amount of taxes we pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the United States, to our international business activities, tax rates, new or revised tax laws, or interpretations of tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to our intercompany arrangements or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our ~~common stock~~operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a “permanent establishment” under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.

Our ability to use our net operating loss carryforwards may be limited.

We have incurred net operating losses during our history. Subject to the ~~voting~~limitations described below, unused net operating losses generally may carry forward to offset future taxable income if we achieve profitability in the future, unless such net operating losses expire under applicable tax laws. Under current law, unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and ~~other rights~~may be carried forward indefinitely, but the deductibility of such federal net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to current federal tax law. In addition, our ability to utilize our federal net operating carryforwards may be limited under Section 382 of the ~~holders~~Internal Revenue Code of 1986, as amended, or the Code. The limitations apply if we experience an “ownership change,” which is generally defined as a greater than 50 percentage point change (by value) in the ownership of our

Table of Contents

equity by certain stockholders or groups of stockholders over a rolling three-year period. Similar provisions of state tax law may also apply to limit the use of our ~~common stock. These provisions include:~~

state net operating loss carryforwards. Past or future changes in our stock ownership, including as a ~~classified board of directors serving staggered terms;~~

~~advance notice requirements to stockholders for matters to be brought at stockholder meetings;~~

~~a supermajority stockholder vote requirement for amending certain provisions~~result of our ~~amended and restated certificate~~initial public offering, some of ~~incorporation and bylaws; and~~

which may be outside of our control, may have triggered or may trigger an ownership change that materially impacts our ability to utilize pre-change net operating loss carryforwards. Moreover, there may be periods during which the ~~right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership~~use of ~~a potential hostile acquirer.~~

~~We are also~~net operating loss carryforwards in various jurisdictions is suspended or otherwise subject to ~~provisions of~~additional limitations. Accordingly, our ability to use our net operating loss carryforwards to offset taxable income may be subject to such limitations or special rules that apply at the Delaware General Corporation law that, in general, prohibit any business combination with a beneficial owner of 15% or more of our common stock for three years unless the holder’s acquisition of our stock was approved in advance by our board of directors or certain other conditions are satisfied.

~~The existence of these provisions~~state level, which could adversely affect ~~the voting power~~our results of ~~holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.~~operations.

Table of Contents



ITEM 2.			UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) Unregistered Sales of Equity Securities during the Three Months Ended September 30, ~~2017~~2023

~~Common Stock Dividend Payable to Carilion~~Not applicable.

We issued 1,321,514 shares of Series A Preferred Stock, par value $0.001 per share, to Carilion Clinic in January 2010, which shares were issued in reliance on the exemptions from registration under the Securities Act provided by Sections 3(a)(9) and 4 (a)(2) thereof. The Series A Preferred Stock accrues dividends at the rate of $0.2815 per share per annum, payable quarterly in arrears. Accrued dividends are payable in shares of our common stock, with the number of shares being equal to the quotient of (i) the cumulative aggregate balance of accrued but unpaid dividends on each share of Series A Preferred Stock divided by (ii) the conversion price of the Series A Preferred Stock, which is currently $4.69159 per share. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2017, the Series A Preferred Stock issued to Carilion has accrued $1,110,773 in dividends. The accrued dividend as of September 30, 2017 will be paid by the issuance of 611,870 shares of our common stock, which we will issue at Carilion’s written request. As the Series A Preferred Stock was issued in reliance on the exemption provided by Section 3(a)(9), the shares of common stock payable as dividends will also be exempt from registration in reliance on Section 3(a)(9) of the Securities Act.

(b) Use of Proceeds from Sale of Registered Equity Securities

Not applicable.

On September 20, 2017, we announced that our board of directors re-instituted our stock repurchase program, authorizing the repurchase of up to $2.0 million of our common stock. An aggregate purchase price of $0.1 million had been expended under this program as of September 30, 2017. Unless extended, the stock repurchase authorization expires on September 19, 2018 and may be terminated, increased or decreased by our board of directors at any time.Not applicable.

~~The following table summarizes repurchases of our common stock during the three months ended September 30, 2017.~~

Total Number of Approximate Dollar
Shares Purchased as Value of Shares that
Total Number of Shares Average Price Paid per Part of a Publicly May Yet be Purchased
Period Purchased Share Announced Program Under the Program
9/1/2017 - 9/30/2017 50,100
$ 1.70
50,100
$ 1,914,745



ITEM 3.			DEFAULTS UPON SENIOR SECURITIES

None.



ITEM 4.			MINE SAFETY DISCLOSURES

Not applicable.



ITEM 5.			OTHER INFORMATION

~~None.~~

Not applicable.

Table of Contents



ITEM 6.			EXHIBITS



Exhibit Number		Description
~~2.1+^~~		~~Asset Purchase Agreement, dated as of August 9, 2017, by and among the Registrant, MACOM Technology Solutions Holdings, Inc., Advanced Photonix, Inc. and Picometrix, LLC.~~
31.1*
~~10.1+~~	~~Transition Services Agreement, dated as of August 9, 2017, by and among Advanced Photonix, Inc., Picometrix, LLC and MACOM Technology Solutions Holdings, Inc.~~

~~31.1~~	Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~31.2~~31.2*		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Registrant’s Quarterly Report on Form 10-Q for the ~~quarter~~three months ended September 30, ~~2017,~~2023, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets at September 30, ~~2017~~2023 and December 31, ~~2016,~~2022, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, ~~2017~~2023 and ~~2016,~~2022, (iii) Consolidated Statements of Comprehensive (Loss))/Income for the three and nine months ended September 30, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, ~~2017~~2023 and ~~2016~~2022 and ~~(iv)~~(v) Notes to Unaudited Consolidated Financial Statements.


104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+	~~Confidential treatment has been requested with respect to portions of this exhibit, indicated by asterisks, which has been filed separately with the SEC.~~
^*		Pursuant to Item 601(b)(2) of Regulation S-K promulgated by the SEC, certain exhibits and schedules to this agreement have been omitted. The Registrant hereby agrees to furnish supplementally to the SEC, upon its request, any or all of such omitted exhibits or schedules.Filed herewith.
**		These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Luna Innovations Incorporated

Date:

November ~~13, 2017~~14, 2023

By:

/s/ ~~Dale Messick~~ George Gomez-Quintero

~~Dale Messick~~George Gomez-Quintero

Chief Financial Officer

(~~principal financial~~Principal Financial and ~~accounting officer and duly authorized officer)~~

Accounting Officer)

4648



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017		2016				2017			2016
	(unaudited)						(unaudited)
Revenues:
Technology development	$	4,590,054	$	4,118,245			$	13,428,428		$	11,772,731
Products and licensing	7,052,094		7,066,908				19,593,648			18,301,631
Total revenues	$	11,642,148	$	11,185,153			$	33,022,076		$	30,074,362
Technology development operating income/(loss)	$	182,776	$	139,134			$	(77,323	)	$	(253,833	)
Products and licensing operating income/(loss)	260,100		(409,835		)		(74,758		)	(2,699,294		)
Total operating income/(loss)	$	442,876	$	(270,701	)		$	(152,081	)	$	(2,953,127	)
Depreciation, technology development	$	87,389	$	87,884			$	267,282		$	264,549
Depreciation, products and licensing	$	117,219	$	300,530			$	688,700		$	827,661
Amortization, technology development	$	28,935	$	23,651			$	95,540		$	141,490
Amortization, products and licensing	$	247,522	$	486,209		��	$	1,178,113		$	1,526,177



	September 30, 2017			December 31, 2016
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	38,514,437		$	12,802,458
Accounts receivable, net	8,940,405			10,269,012
Inventory	7,300,035			6,848,835
Prepaid expenses and other current assets	924,196			1,375,659
Current assets held for sale	—			5,801,629
Total current assets	55,679,073			37,097,593
Property and equipment, net	3,145,769			3,482,687
Intangible assets, net	3,264,285			3,367,217
Goodwill	502,000			502,000
Long term receivable- sale of HSOR business	4,000,000			—
Other assets	18,024			38,194
Non-current assets held for sale	—			10,509,282
Total assets	$	66,609,151		$	54,996,973
Liabilities and stockholders’ equity
Liabilities:
Current liabilities:
Current portion of long-term debt obligations	$	1,833,333		$	1,833,333
Current portion of capital lease obligations	49,070			52,128
Accounts payable	2,188,776			2,954,742
Accrued liabilities	9,586,554			7,913,544
Deferred revenue	897,023			837,906
Current liabilities held for sale	—			2,376,703
Total current liabilities	14,554,756			15,968,356
Long-term deferred rent	1,221,170			1,319,402
Long-term debt obligations	1,057,263			2,420,032
Long-term capital lease obligations	79,246			114,940
Non-current liabilities held for sale	—			84,555
Total liabilities	16,912,435			19,907,285
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $0.001, 1,321,514 shares authorized, issued and outstanding at September 30, 2017 and December 31, 2016	1,322			1,322
Common stock, par value $0.001, 100,000,000 shares authorized, 28,402,887 and 27,988,104 shares issued, 27,815,060 and 27,541,277 shares outstanding at September 30, 2017 and December 31, 2016	29,074			28,600
Treasury stock at cost, 587,827 and 446,827 shares at September 30, 2017 and December 31, 2016	(746,007		)	(517,987		)
Additional paid-in capital	83,204,263			82,451,958
Accumulated deficit	(32,791,936		)	(46,874,205		)
Total stockholders’ equity	49,696,716			35,089,688
Total liabilities and stockholders’ equity	$	66,609,151		$	54,996,973



	September 30, 2017
	(unaudited)
Sale price	$	33,500,000
Less: transition services payments	(1,500,000		)
Adjusted purchase price	32,000,000

Assets held for sale	(16,851,540		)
Liabilities held for sale	2,330,052
Transaction costs	(873,473		)
Income tax expense	(1,508,373		)
Gain on sale of discontinued operations	$	15,096,666



	September 30, 2017		December 31, 2016
	(unaudited)
Finished goods	$	2,234,828	$	1,952,885
Work-in-process	844,083		714,867
Raw materials	4,221,124		4,181,083
Total inventory	$	7,300,035	$	6,848,835



	Options Outstanding							Options Exercisable
	Number of Shares		Price per Share Range	Weighted Average Exercise Price		Aggregate Intrinsic Value (1)		Number of Shares	Weighted Average Exercise Price		Aggregate Intrinsic Value (1)
Balance, January 1, 2017	2,857,114		$0.61 - $6.83	$	1.89	$	107,063	2,367,630	$	1.93	$	101,071
Granted	80,000		$1.51 - $1.54	$	1.53
Exercised	(31,953	)	$0.82 - $1.38	$	0.95
Canceled	(170,590	)	$1.40 - $6.83	$	2.27
Balance, September 30, 2017	2,734,571		$0.61 - $6.55	$	1.87	$	585,292	2,619,914	$	1.88	$	555,926



	Number of Unvested Shares		Weighted Average Grant Date Fair Value		Aggregate Value of Unvested Shares
Balance, January 1, 2017	829,998		$	1.19	$	988,763
Granted	428,865		$	1.54	660,752
Vested	(442,498	)	$	1.20	(531,853		)
Repurchased	—		$	—	—
Forfeitures	(51,667	)	$	1.14	(58,917		)
Balance, September 30, 2017	764,698		$	1.38	$	1,058,745



	Number of RSUs			Intrinsic Value
	Issued	Unvested	Weighted Average Grant Date Fair Value per Share	Outstanding		Unvested
Balance, January 1, 2017	393,012	—	$1.37	$	577,728	$	—
Granted	55,748	—	$1.57
Vested	—	—	$0.00
Forfeitures	—	—	$0.00
Converted	—	—	$0.00
Balance, September 30, 2017	448,760	—	$1.39	$	758,404	$	—



	Preferred Stock		Common Stock				Treasury Stock			Additional Paid-in Capital
	Shares	$	Shares		$		Shares	$		$
Balance, January 1, 2017	1,321,514	1,322	27,541,277		28,600		446,827	(517,987	)	82,451,958
Exercise of stock options	—	—	31,953		32		—	—		819
Share-based compensation	—	—	299,000		299		—	—		476,128
Non-cash compensation	—	—	135,497		136		—	—		178,035
Stock dividends to Carilion Clinic⁽¹⁾	—	—	—		59		—	—		97,271
Forfeitures of restricted stock grants	—	—	(51,667	)	(52	)	—	—		—
Repurchase of common stock	—	—	(141,000	)	—		141,000	(228,020	)	52
Balance, September 30, 2017	1,321,514	1,322	27,815,060		29,074		587,827	(746,007	)	83,204,263



				Total Number of	Approximate Dollar
				Shares Purchased as	Value of Shares that
	Total Number of Shares	Average Price Paid per		Part of a Publicly	May Yet be Purchased
Period	Purchased	Share		Announced Program	Under the Program
9/1/2017 - 9/30/2017	50,100	$	1.70	50,100	$	1,914,745